e424b5
Filed Pursuant to
Rule 424(b)(5)
Registration
No. 333-164348
PROSPECTUS SUPPLEMENT
(To Prospectus dated January 25, 2010)
14,000,000 Shares
Conexant Systems,
Inc.
Common Stock
Conexant Systems, Inc. is offering 14,000,000 shares of its
common stock to be sold in this offering.
Our common stock is listed on the Nasdaq Global Select Market
under the symbol CNXT. The last reported sale price
of our common stock on March 4, 2010 was $4.39 per share.
See Risk Factors on
page S-8
of this prospectus supplement to read about factors you should
consider before buying shares of the common stock.
Neither the Securities and Exchange Commission nor any other
regulatory body has approved or disapproved of these securities
or passed upon the accuracy or adequacy of this prospectus
supplement or the accompanying prospectus. Any representation to
the contrary is a criminal offense.
|
|
|
|
|
|
|
|
|
|
|
Per Share
|
|
Total
|
|
Initial price to public
|
|
$
|
4.00
|
|
|
$
|
56,000,000
|
|
Underwriting discount
|
|
$
|
0.22
|
|
|
$
|
3,080,000
|
|
Proceeds, before expenses, to Conexant Systems, Inc.
|
|
$
|
3.78
|
|
|
$
|
52,920,000
|
|
To the extent that the underwriters sell more than
14,000,000 shares of common stock, the underwriters have
the option to purchase up to an additional 2,100,000 shares
from us at the initial price to public less the underwriting
discount.
The underwriters expect to deliver the shares against payment in
New York, New York on March 10, 2010.
Sole
Book-Running
Manager
Goldman, Sachs &
Co.
Co-Manager
Oppenheimer & Co.
Prospectus supplement dated March 4, 2010.
TABLE OF
CONTENTS
Prospectus
Supplement
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
ii
|
|
|
|
|
S-1
|
|
|
|
|
S-8
|
|
|
|
|
S-24
|
|
|
|
|
S-26
|
|
|
|
|
S-27
|
|
|
|
|
S-29
|
|
|
|
|
S-30
|
|
|
|
|
S-34
|
|
|
|
|
S-36
|
|
|
|
|
S-36
|
|
|
|
|
S-36
|
|
|
|
|
S-37
|
|
Prospectus
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
8
|
|
|
|
|
18
|
|
|
|
|
19
|
|
|
|
|
20
|
|
|
|
|
21
|
|
|
|
|
21
|
|
i
ABOUT THIS
PROSPECTUS SUPPLEMENT
On January 15, 2010, we filed with the Securities and
Exchange Commission (the SEC) a registration
statement on
Form S-3
(File
No. 333-164348)
utilizing a shelf registration process relating to the
securities described in this prospectus supplement, which
registration statement was declared effective on
January 25, 2010.
This document is in two parts. The first part is this prospectus
supplement, which describes the specific terms of this common
stock offering and also adds to and updates information
contained in the accompanying prospectus and the documents
incorporated by reference into the prospectus. The second part,
the accompanying prospectus, gives more general information,
some of which does not apply to this offering.
If there is a conflict between the information contained in this
prospectus supplement and the accompanying prospectus or any
document incorporated by reference herein or therein, you should
rely on the information contained in this prospectus supplement.
However, if any statement in one of these documents is
inconsistent with a statement in another document having a later
date for example, a document incorporated by
reference in this prospectus supplement and the accompanying
prospectus the statement in the document having the
later date modifies or supersedes the earlier statement.
You should rely only on the information contained in this
prospectus supplement, the accompanying prospectus, any free
writing prospectus that we have authorized to be distributed to
you or information incorporated by reference herein or in the
accompanying prospectus. Neither we nor the underwriters have
authorized anyone to provide you with additional or different
information. We are offering to sell, and seeking offers to buy,
common stock only in jurisdictions where offers and sales are
permitted. The information contained in this prospectus
supplement and the accompanying prospectus is accurate only as
of the date on the front of those documents and the information
contained in any document incorporated by reference into this
prospectus supplement or the accompanying prospectus is accurate
only as of its filing date.
No action is being taken in any jurisdiction outside the
United States to permit a public offering of the common stock or
possession or distribution of this prospectus supplement or the
accompanying prospectus in that jurisdiction. Persons who come
into possession of this prospectus supplement or the
accompanying prospectus in jurisdictions outside the United
States are required to inform themselves about and to observe
any restrictions as to this offering and the distribution of
this prospectus supplement and the accompanying prospectus
applicable to that jurisdiction.
Unless we have indicated otherwise, or the context otherwise
requires, references in this prospectus supplement and the
accompanying prospectus to the Company,
we, us and our or similar
terms are to Conexant Systems, Inc. and its subsidiaries.
ii
SUMMARY
This summary highlights certain information about us, this
offering and information appearing elsewhere in this prospectus
supplement, the accompanying prospectus and the documents
incorporated by reference herein and therein. This summary is
not complete and does not contain all of the information that
you should consider before investing. After you read this
summary, to fully understand this offering and its consequences
to you, you should read and carefully consider the more detailed
information and financial statements and related notes that we
include in
and/or
incorporate by reference into this prospectus supplement and the
accompanying prospectus, including the information set forth
under the heading Risk Factors.
Conexant Systems,
Inc.
Our
Business
We design, develop and sell semiconductor system solutions,
comprised of semiconductor devices, software and reference
designs, for imaging, audio, embedded-modem and video
applications. These solutions include a comprehensive portfolio
of imaging solutions for multifunction printers, fax platforms
and connected frame market segments. Our audio
solutions include high-definition (HD) audio
integrated circuits, HD audio codecs, and
speakers-on-a-chip
solutions for personal computers (PCs), PC
peripheral sound systems, audio subsystems, speakers, notebook
docking stations,
voice-over-IP
speakerphones, intercom, door phone and audio-enabled
surveillance applications. We also offer a full suite of
embedded-modem solutions for set-top boxes,
point-of-sale
systems, home automation and security systems, and desktop and
notebook PCs. Additional products include decoders and media
bridges for video surveillance and security applications, and
system solutions for analog video-based multimedia applications.
We market and sell our semiconductor products and system
solutions directly to leading original equipment manufacturers
(OEMs) of communication electronics products and
indirectly through electronic components distributors. We also
sell our products to third-party electronic manufacturing
service providers, who manufacture products incorporating our
semiconductor products for OEMs.
Corporate
Information
We have been operating in the communications semiconductor
business since 1996, including as part of the semiconductor
systems business of Rockwell International Corporation (now
Rockwell Automation, Inc.) (Rockwell), and we have
been an independent public company since January 1999, following
our spin-off from Rockwell. Since then, we have transformed our
company from a broad-based communications semiconductor supplier
into a fabless communications semiconductor supplier focused on
delivering the technology and products for imaging, audio,
embedded-modem and video applications.
Our principal corporate office is located at 4000 MacArthur
Boulevard, Newport Beach, California 92660, and our main
telephone number at that location is
(949) 483-4600.
We maintain a website at www.conexant.com. The
information on, or accessible through, our website is not
intended to be incorporated into this prospectus supplement or
the accompanying prospectus.
S-1
The
Transactions
Senior Secured
Notes Offering
On March 3, 2010, we entered into an agreement to issue and
sell $175 million aggregate principal amount of 11.25%
senior secured notes due 2015 in a private transaction that is
not subject to the registration requirements of the Securities
Act of 1933, as amended. We intend to use the net proceeds from
the senior secured notes offering, if any, to repurchase any of
our 4.00% convertible subordinated notes due March 2026, or the
convertible subordinated notes, that are tendered and accepted
for purchase pursuant to our pending tender offer discussed
below. Any excess proceeds from the senior secured notes
offering will be used for general corporate purposes, including
repurchasing from time to time in the open market or otherwise,
in our sole discretion, any remaining convertible subordinated
notes or redeeming any convertible subordinated notes that
remain outstanding as of March 1, 2011 as soon as
practicable after such date, in accordance with the terms of the
indenture governing the convertible subordinated notes. The
completion of the senior secured notes offering is not a
condition to the issuance of common stock pursuant to this
offering and the completion of this offering is not a condition
to the senior secured notes offering.
Offer to Purchase
our 4.00% Convertible Subordinated Notes due March
2026
On March 3, 2010, we commenced a tender offer to purchase
for cash any and all of the outstanding $232.4 million
aggregate principal amount of the convertible subordinated
notes. The tender offer is being made pursuant to an offer to
purchase, dated March 3, 2010, which more fully sets forth
the terms and conditions of the tender offer. Our obligation to
purchase the convertible subordinated notes in the tender offer
is conditioned upon, among other things, the consummation of
this offering and the senior secured notes offering discussed
above, which, together with our available cash on hand, would
result in net proceeds to us sufficient to pay the total
consideration owed to tendering holders. However, the completion
of the tender offer is not a condition to the issuance of the
common stock pursuant to this offering or the senior secured
notes offering discussed above.
We collectively refer to the issuance of the common stock
pursuant to this offering, the senior secured notes offering and
the tender offer as the Transactions.
S-2
The
Offering
|
|
|
Common stock offered by us |
|
14,000,000 shares |
|
Common stock to be outstanding immediately after this offering |
|
79,081,404 shares |
|
Use of proceeds |
|
We intend to use the net proceeds from this offering and our
senior secured notes offering, together with available cash on
hand, to repurchase any of our convertible subordinated notes
tendered and accepted for purchase pursuant to our pending
tender offer. We may use any remaining net proceeds from this
offering for general corporate purposes including repurchasing
from time to time in the open market or otherwise, in our sole
discretion, any remaining convertible subordinated notes or
redeeming any convertible subordinated notes that remain
outstanding as of March 1, 2011 as soon as practicable after
such date, in accordance with the terms of the indenture
governing the convertible subordinated notes. This offering is
not conditioned on the completion of the tender offer or our
senior secured notes offering. See Use of Proceeds
on
page S-26
and Summary The Transactions on
page S-2. |
|
NASDAQ Global Select Market symbol |
|
CNXT |
|
Risk Factors |
|
See Risk Factors beginning on
page S-8
and other information included in this prospectus supplement for
a discussion of factors you should carefully consider before
deciding to invest in shares of the common stock. |
The number of shares of our common stock outstanding after this
offering is based on 65,081,404 shares of our common stock
outstanding as of February 22, 2010. Unless otherwise
indicated, the number of shares of our common stock presented in
this prospectus supplement excludes the following:
|
|
|
|
|
3,290,899 shares of our common stock that may be issued
upon exercise of stock options outstanding under our stock
option and long-term incentive plans as of that date, at a
weighted average exercise price of $24.50 per share;
|
|
|
|
3,521,666 shares of our common stock that may be issued
upon the vesting of restricted stock units outstanding under our
long-term incentive plans as of that date;
|
|
|
|
9,755,491 shares of our common stock available as of that
date for future grant or issuance pursuant to our stock option
and long-term incentive plans for employees, directors and
consultants; and
|
|
|
|
up to 2,100,000 shares of our common stock that may be
purchased by the underwriters to cover over-allotments, if any.
|
S-3
Summary
Consolidated Financial Information
The following table presents summary consolidated financial
information. The summary consolidated financial information for
the three fiscal years ended October 2, 2009,
October 3, 2008 and September 28, 2007 has been
derived from our audited consolidated financial statements
included in our Current Report on
Form 8-K
filed with the SEC on February 8, 2010, which is
incorporated herein by reference. The summary consolidated
financial information for the fiscal quarters ended
January 1, 2010 and January 2, 2009 and as of
January 1, 2010 has been derived from our unaudited
condensed consolidated financial statements included in our
Quarterly Report on
Form 10-Q
for the fiscal quarter ended January 1, 2010, which is
incorporated herein by reference. See Where You Can Find
More Information and Incorporation of Certain
Documents by Reference. On October 3, 2009, we
adopted FASB ASC
470-20 (FSP
APB 14-1,
Accounting for Convertible Debt Instruments That May Be
Settled in Cash upon Conversion (Including Partial Cash
Settlement), or FASB ASC
470-20 (FSP
APB 14-1)).
The summary consolidated financial information presented below
has been recast from the financial statements included in our
Annual Report on
Form 10-K
for the fiscal year ended October 2, 2009 to reflect the
retrospective application of FASB ASC
470-20 (FSP
APB 14-1).
In addition, in our Quarterly Report on
Form 10-Q
for the fiscal quarter ended January 1, 2010, which is
incorporated by reference herein, we adjusted our unaudited
condensed consolidated financial statements for the fiscal
quarter ended January 2, 2009 to reflect the retrospective
application of FASB ASC
470-20 (FSP
APB 14-1).
The summary consolidated financial information should be read in
conjunction with Managements Discussion and Analysis
of Financial Condition and Results of Operations and our
consolidated financial statements and notes related thereto
incorporated by reference into this prospectus supplement and
the accompanying prospectus. Operating results for the fiscal
quarter ended January 1, 2010 are not necessarily
indicative of the operating results to be expected for the full
fiscal year ending October 1, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Quarter Ended
|
|
|
Fiscal Year Ended
|
|
|
|
January 1,
|
|
|
January 2,
|
|
|
October 2,
|
|
|
October 3,
|
|
|
September 28,
|
|
|
|
2010
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except per share amounts and ratios)
|
|
|
Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues
|
|
$
|
61,813
|
|
|
$
|
57,463
|
|
|
$
|
208,427
|
|
|
$
|
331,504
|
|
|
$
|
360,703
|
|
Cost of goods sold(1)
|
|
|
24,204
|
|
|
|
24,946
|
|
|
|
86,674
|
|
|
|
137,251
|
|
|
|
161,972
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin
|
|
|
37,609
|
|
|
|
32,517
|
|
|
|
121,753
|
|
|
|
194,253
|
|
|
|
198,731
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development(1)
|
|
|
13,245
|
|
|
|
13,567
|
|
|
|
51,351
|
|
|
|
58,439
|
|
|
|
91,885
|
|
Selling, general and administrative(1)
|
|
|
12,402
|
|
|
|
17,866
|
|
|
|
62,740
|
|
|
|
77,905
|
|
|
|
80,893
|
|
Amortization of intangible assets
|
|
|
396
|
|
|
|
517
|
|
|
|
2,976
|
|
|
|
3,652
|
|
|
|
9,555
|
|
Asset impairments(2)
|
|
|
|
|
|
|
|
|
|
|
5,672
|
|
|
|
277
|
|
|
|
225,380
|
|
Gain on sale of intellectual property(3)
|
|
|
|
|
|
|
(12,858
|
)
|
|
|
(12,858
|
)
|
|
|
|
|
|
|
|
|
Special charges(4)
|
|
|
346
|
|
|
|
10,577
|
|
|
|
18,983
|
|
|
|
18,682
|
|
|
|
8,360
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
26,389
|
|
|
|
29,669
|
|
|
|
128,864
|
|
|
|
158,955
|
|
|
|
416,073
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
11,220
|
|
|
|
2,848
|
|
|
|
(7,111
|
)
|
|
|
35,298
|
|
|
|
(217,342
|
)
|
Interest expense(5)
|
|
|
9,503
|
|
|
|
8,626
|
|
|
|
34,693
|
|
|
|
40,713
|
|
|
|
48,798
|
|
Other (income) expense, net
|
|
|
(7,204
|
)
|
|
|
1,927
|
|
|
|
(5,025
|
)
|
|
|
9,223
|
|
|
|
(36,505
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S-4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Quarter Ended
|
|
|
Fiscal Year Ended
|
|
|
|
January 1,
|
|
|
January 2,
|
|
|
October 2,
|
|
|
October 3,
|
|
|
September 28,
|
|
|
|
2010
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands, except per share amounts and ratios)
|
|
|
Income (loss) from continuing operations before income taxes and
gain (loss) on equity method investments
|
|
|
8,921
|
|
|
|
(7,705
|
)
|
|
|
(36,779
|
)
|
|
|
(14,638
|
)
|
|
|
(229,635
|
)
|
(Benefit) provision for income taxes
|
|
|
(230
|
)
|
|
|
468
|
|
|
|
871
|
|
|
|
849
|
|
|
|
798
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations before (loss) gain on
equity method investments
|
|
|
9,151
|
|
|
|
(8,173
|
)
|
|
|
(37,650
|
)
|
|
|
(15,487
|
)
|
|
|
(230,433
|
)
|
(Loss) gain on equity method investments
|
|
|
(454
|
)
|
|
|
(846
|
)
|
|
|
(2,807
|
)
|
|
|
2,804
|
|
|
|
51,182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
|
8,697
|
|
|
|
(9,019
|
)
|
|
|
(40,457
|
)
|
|
|
(12,683
|
)
|
|
|
(179,251
|
)
|
Gain on sale of discontinued operations, net of tax(6)
|
|
|
|
|
|
|
|
|
|
|
39,170
|
|
|
|
6,268
|
|
|
|
|
|
Loss from discontinued operations, net of tax(1)(6)
|
|
|
(363
|
)
|
|
|
(11,973
|
)
|
|
|
(17,521
|
)
|
|
|
(306,670
|
)
|
|
|
(235,056
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
8,334
|
|
|
$
|
(20,992
|
)
|
|
$
|
(18,808
|
)
|
|
$
|
(313,085
|
)
|
|
$
|
(414,307
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per share from continuing operations
basic and diluted
|
|
$
|
0.14
|
|
|
$
|
(0.18
|
)
|
|
$
|
(0.81
|
)
|
|
$
|
(0.26
|
)
|
|
$
|
(3.67
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain per share from sale of discontinued operations
basic and diluted
|
|
$
|
|
|
|
$
|
|
|
|
$
|
0.78
|
|
|
$
|
0.13
|
|
|
$
|
0.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share from discontinued operations basic
|
|
$
|
0.00
|
|
|
$
|
(0.24
|
)
|
|
$
|
(0.35
|
)
|
|
$
|
(6.21
|
)
|
|
$
|
(4.80
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per share from discontinued operations diluted
|
|
$
|
0.00
|
|
|
$
|
(0.24
|
)
|
|
$
|
(0.35
|
)
|
|
$
|
(6.21
|
)
|
|
$
|
(4.80
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
$
|
0.14
|
|
|
$
|
(0.42
|
)
|
|
$
|
(0.38
|
)
|
|
$
|
(6.34
|
)
|
|
$
|
(8.47
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
$
|
0.14
|
|
|
$
|
(0.42
|
)
|
|
$
|
(0.38
|
)
|
|
$
|
(6.34
|
)
|
|
$
|
(8.47
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selected Other Financial Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratio of Earnings to fixed charges(7)
|
|
|
0.15
|
|
|
|
0.13
|
|
|
|
|
|
|
|
0.81
|
|
|
|
|
|
S-5
|
|
|
|
|
|
|
|
|
|
|
As of January 1, 2010
|
|
|
|
|
|
|
Pro Forma for the
|
|
Balance Sheet Data:
|
|
Actual
|
|
|
Transactions(8)
|
|
|
Working capital(9)
|
|
$
|
65,770
|
|
|
$
|
48,750
|
|
Total assets
|
|
|
273,747
|
|
|
|
256,666
|
|
Short-term debt
|
|
|
|
|
|
|
|
|
Long-term debt, net of discount
|
|
|
215,902
|
|
|
|
173,360
|
|
Shareholders deficit
|
|
|
(66,650
|
)
|
|
|
(14,177
|
)
|
|
|
|
(1) |
|
We adopted FASB ASC
718-10
(Statement of Financial Accounting Standards (SFAS)
No. 123(R), Share-Based Payment,) on
October 1, 2005. As a result, stock-based compensation
expense included within cost of goods sold, research and
development expense, and selling, general and administrative
expense in the fiscal years ended October 2, 2009,
October 3, 2008 and September 28, 2007 is based on the
fair value of all stock options, stock awards and employee stock
purchase plan shares. Non-cash employee stock-based compensation
expense included in our consolidated statements of operations
was as follows (in thousands): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Quarter Ended
|
|
|
Fiscal Year Ended
|
|
|
|
January 1,
|
|
|
January 2,
|
|
|
October 2,
|
|
|
October 3,
|
|
|
September 28,
|
|
|
|
2010
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Cost of goods sold
|
|
$
|
58
|
|
|
$
|
37
|
|
|
$
|
247
|
|
|
$
|
370
|
|
|
$
|
426
|
|
Research and development
|
|
|
401
|
|
|
|
435
|
|
|
|
869
|
|
|
|
2,725
|
|
|
|
6,157
|
|
Selling, general and administrative
|
|
|
1,037
|
|
|
|
1,713
|
|
|
|
3,736
|
|
|
|
9,185
|
|
|
|
7,271
|
|
Income (loss) from discontinued operations, net of tax
|
|
|
(35
|
)
|
|
|
188
|
|
|
|
868
|
|
|
|
3,589
|
|
|
|
5,897
|
|
|
|
|
(2) |
|
In the fiscal year ended September 28, 2007, we recorded
$184.7 million of goodwill impairment charges,
$30.3 million of intangible impairment charges and
$6.1 million of property, plant and equipment impairment
charges associated with our Embedded Wireless Network products. |
|
(3) |
|
In the fiscal year ended October 2, 2009, we recorded a
$12.9 million gain on sale of intellectual property. |
|
(4) |
|
Special charges include the following related to the settlement
of legal matters and restructuring charges (in thousands): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Quarter Ended
|
|
Fiscal Year Ended
|
|
|
January 1,
|
|
January 2,
|
|
October 2,
|
|
October 3,
|
|
September 28,
|
|
|
2010
|
|
2009
|
|
2009
|
|
2008
|
|
2007
|
|
Legal settlements
|
|
$
|
|
|
|
$
|
3,650
|
|
|
$
|
3,475
|
|
|
$
|
|
|
|
$
|
1,497
|
|
Restructuring charges
|
|
|
346
|
|
|
|
6,557
|
|
|
|
15,116
|
|
|
|
11,539
|
|
|
|
7,227
|
|
|
|
|
(5) |
|
Our interest expense for the fiscal year ended October 2,
2009 would have been $26.9 million, after giving pro forma
effect to (i) the Transactions, assuming all of our
convertible subordinated notes were tendered and accepted for
purchase pursuant to our pending tender offer, and (ii) the
repurchases by us during the fiscal quarter ended
January 1, 2010 of certain of our convertible subordinated
notes and our floating rate senior secured notes due 2010,
assuming the Transactions and repurchases had occurred on
October 4, 2008. We cannot assure you that any of the
outstanding convertible subordinated notes will be tendered
pursuant to our pending tender offer. For each
$23.2 million aggregate principal amount of outstanding
convertible subordinated notes not tendered and accepted for
purchase pursuant to the tender offer, for the fiscal year ended
October 2, 2009, our interest expense would have increased
by $2.3 million. |
S-6
|
|
|
(6) |
|
As a result of our decision to sell certain assets and
liabilities of the Broadband Access (BBA) and
Broadband Media Processing (BMP) business units in
the fiscal years ended October 2, 2009 and October 3,
2008, respectively, the results of the BMP and BBA business and
the gain on sale of the BMP business are reported as
discontinued operations for all periods presented. |
|
(7) |
|
For purposes of calculating this ratio, earnings consist of
income (loss) from continuing operations before (i) income
taxes and (ii) income (loss) from equity method
investments, plus the addition of (i) distributed income of
equity investees and (ii) fixed charges. Fixed charges
consist of interest expense, including amortization of debt
issuance costs, and the portion of rent expense which we believe
is representative of the interest component of rental expense.
For the fiscal years ended October 2, 2009 and
September 28, 2007, earnings were insufficient to cover
fixed charges by approximately $35.9 million and
$229.2 million, respectively. |
|
(8) |
|
Gives pro forma effect to the use of net proceeds from this
offering and our senior secured notes offering, and available
cash on hand, to repurchase all of the outstanding convertible
subordinated notes, assuming that all of the outstanding
convertible subordinated notes are tendered and accepted for
purchase pursuant to our pending tender offer. We cannot assure
you that any of the outstanding convertible subordinated notes
will be tendered pursuant to our pending tender offer. For each
$23.2 million aggregate principal amount of outstanding
convertible subordinated notes not tendered and accepted for
purchase pursuant to the tender offer, at January 1, 2010,
our total long-term debt would have increased by
$21.6 million, net of debt discount of $1.6 million. |
|
(9) |
|
Working capital is defined as current assets minus current
liabilities. |
S-7
RISK
FACTORS
Investing in our common stock involves a high degree of
risk. You should carefully consider the following risk factors
as well as the other information contained in this prospectus
supplement and the accompanying prospectus and incorporated by
reference into this prospectus supplement and the accompanying
prospectus before deciding whether to invest in our common
stock. Any of the following risks could materially and adversely
affect our business, financial condition or results of
operations. As a result, you could lose all or part of your
investment in our common stock. Additional risks and
uncertainties not currently known to us or that we currently
deem to be immaterial may also materially and adversely affect
our business, financial condition or results of operations. In
that case, the trading price of our common stock could decline,
and you may lose some or all of your investment. In connection
with the forward-looking cautionary statements that appear in
this prospectus supplement and the accompanying prospectus, you
should also carefully review the cautionary statement referred
to under Cautionary Note Regarding Forward-Looking
Statements.
Risks Related to
Our Business
After the
completion of the Transactions, even if all of the outstanding
convertible subordinated notes are tendered pursuant to our
pending tender offer, we will still have a significant amount of
debt and will require a significant amount of cash to service
our debt. We face a risk that capital needed for our business
and to repay our debt obligations will not be available when we
need it.
As of January 1, 2010, our total outstanding indebtedness
was approximately $215.9 million, net of debt discount of
$16.5 million, and our total consolidated
stockholders deficit was $66.7 million. Our total
outstanding indebtedness at January 1, 2010 would have been
$175.0 million, consisting entirely of our 11.25% senior
secured notes referred to in Summary The
Transaction, and our interest expense for the fiscal year
ended October 2, 2009 would have been approximately
$26.9 million, after giving pro forma effect to
(i) the Transactions, assuming all of our convertible
subordinated notes were tendered and accepted for purchase
pursuant to our pending tender offer, and (ii) the
repurchases by us during the fiscal quarter ended
January 1, 2010 of certain of our outstanding convertible
subordinated notes and our floating rate senior secured notes
due 2010, assuming the Transactions and repurchases had occurred
on October 4, 2008. We also have a $15.0 million
accounts receivable financing facility available to us that had
no amounts borrowed as of January 1, 2010. Our accounts
receivable financing facility matures on December 31, 2010.
This offering is not conditioned upon the completion of our
pending tender offer or senior secured notes offering. We cannot
assure you that we will be successful in consummating our senior
secured notes offering or our tender offer on a timely basis or
at all, or that any of the outstanding convertible subordinated
notes will be tendered pursuant to our pending tender offer. If
we fail to consummate the tender offer or a significant
principal amount of the convertible subordinated notes is not
tendered pursuant to the tender offer, we will have even greater
amounts of debt outstanding. For each $23.2 million
aggregate principal amount of outstanding convertible
subordinated notes not tendered and accepted for purchase
pursuant to the tender offer, our total outstanding indebtedness
at January 1, 2010, would have increased by
$21.6 million, net of debt discount of $1.6 million,
and our interest expense for the fiscal year ended
October 2, 2009, would have increased by $2.3 million.
If the tender offer is not consummated or a portion of our
convertible subordinated notes remain outstanding after the
tender offer, holders of our convertible subordinated notes may
be able to require us to repurchase, for cash, all or part of
their convertible subordinated notes on March 1, 2011 at a
price of 100% of the principal amount thereof, plus accrued and
unpaid interest. We may not be able to repurchase any
convertible subordinated notes that we are required to
repurchase on March 1, 2011 because we may not have
sufficient funds. Our failure to meet our repurchase obligations
with respect to any convertible subordinated notes would cause a
default under the
S-8
indenture governing the convertible subordinated notes. Even if
we are able to meet our repurchase obligations with respect to
the convertible subordinated notes, we cannot assure you that we
will have sufficient cash and cash equivalents to operate our
business or to service our remaining indebtedness.
If we cannot meet our repurchase obligations under the indenture
governing the convertible subordinated notes or make scheduled
payments on any of our outstanding indebtedness, we will be in
default and, as a result:
|
|
|
|
|
our debt holders could declare all outstanding principal and
interest to be due and payable; and
|
|
|
|
we could be forced into bankruptcy or liquidation, which could
result in you losing your investment in shares of our common
stock.
|
Recent tightening of the credit markets and unfavorable and
uncertain economic conditions during our last two fiscal years
have led to a low level of liquidity in many financial markets
and extreme volatility in the credit and equity markets. There
is no assurance that we will be able to access the equity
markets in future periods or on similar terms and conditions as
we have in the past. If signs of improvement in the global
economy do not progress as expected and the economic slowdown
continues or worsens, our business, financial condition, cash
flow and results of operations will be adversely affected. If
that happens, our ability to access the capital or credit
markets may worsen and we may not be able to obtain sufficient
capital to repay our indebtedness, including the notes issued
pursuant to our senior secured notes offering, when it becomes
due. In the event we are unable to satisfy or refinance all of
our outstanding debt obligations as the obligations are required
to be paid, including any remaining convertible subordinated
notes not tendered and accepted for purchase in our tender
offer, we will be required to consider strategic and other
alternatives, including, among other things, the sale of assets
to generate funds, the negotiation of revised terms of our
indebtedness or other restructuring alternatives such as
additional exchanges of our existing indebtedness obligations
for new securities or additional equity offerings. Further, we
may not be able to refinance any portion of this debt on
favorable terms or at all. Our failure to satisfy or refinance
any of our indebtedness obligations as they come due, including
through additional exchanges of new securities for existing
indebtedness obligations or additional equity offerings, would
result in a cross default and potential acceleration of our
remaining indebtedness obligations, would have a material
adverse effect on our business, liquidity and ability to operate
as a going concern.
Additionally, in the future, we may need to make strategic
investments and acquisitions to help us grow our business, which
may require additional capital resources. We cannot assure you
that the capital required to fund these investments and
acquisitions will be available in the future.
Our operating
and financial flexibility is limited by the terms of the
agreement governing our accounts receivable financing facility
and will be limited by the terms of the indenture governing our
senior secured notes.
The agreement governing our accounts receivable financing
facility contains, and the indenture governing our senior
secured notes will contain, financial and other covenants that
may limit our ability to, or prevent us from, taking certain
actions that we believe are in the best interests of our
business and our stockholders. For example, the indenture
governing our senior secured notes will contain covenants that
restrict, subject to certain exceptions, our ability and the
ability of our subsidiaries who are guarantors of our senior
secured notes to incur or guarantee additional indebtedness or
issue certain redeemable or preferred stock; repurchase capital
stock; pay dividends on or make other distributions in respect
of our capital stock or make other restricted payments; make
certain investments; create liens; redeem junior debt; sell
certain assets; consolidate, merge, sell or otherwise dispose of
all or substantially all of our assets; enter into certain types
of transactions with affiliates; and enter into sale-leaseback
transactions. The restrictions imposed by the agreement
governing our accounts receivable financing facility and the
indenture governing our senior secured notes may
S-9
prevent us from taking actions that could help to grow our
business or increase the value of our securities.
We are a much
smaller company than in the recent past and dependent on fewer
products for our success.
We are a much smaller company than in the recent past with a
narrower, less diversified and more focused portfolio of
products. Our smaller size could cause our cash flow and growth
prospects to be more volatile and make us more vulnerable to
focused competition. As a smaller company, we will have less
capital available for research and development and for strategic
investments and acquisitions. As a smaller company, we will be
subject to greater revenue fluctuations if our older product
lines sales were to decline faster than we anticipate. We could
also face greater challenges in satisfying or refinancing our
debt obligations as they become due. In addition, we may not be
able to appropriately restructure our supporting functions to
fit the needs of a smaller company.
We are subject
to the risks of doing business internationally.
For the fiscal quarters ended January 1, 2010 and
January 2, 2009, net revenues from customers located
outside of the United States (U.S.), primarily in
the Asia-Pacific region, represented approximately 94% of our
total net revenues. In addition, many of our key suppliers are
located outside of the U.S. Our international operations
consist of research and development, sales offices, and other
general and administrative functions. Our international
operations are subject to a number of risks inherent in
operating abroad. These include, but are not limited to, risks
regarding:
|
|
|
|
|
difficulty in obtaining distribution and support;
|
|
|
|
local economic and political conditions;
|
|
|
|
limitations on our ability under local laws to protect our
intellectual property;
|
|
|
|
currency exchange rate fluctuations;
|
|
|
|
disruptions of commerce and capital or trading markets due to or
related to terrorist activity, armed conflict, or natural
disasters;
|
|
|
|
restrictive governmental actions, such as restrictions on the
transfer or repatriation of funds and trade protection measures,
including export duties and quotas and customs duties and
tariffs;
|
|
|
|
changes in legal or regulatory requirements;
|
|
|
|
the laws and policies of the U.S. and other countries
affecting trade, foreign investment and loans, and import or
export licensing requirements; and
|
|
|
|
tax laws, including the cost of services provided and products
sold between us and our subsidiaries which are subject to review
by taxing authorities.
|
Approximately $24.8 million of our $59.1 million of
cash and cash equivalents at January 1, 2010 was located in
foreign countries where we conduct business, including
approximately $14.2 million in India and $2.2 million
in China. These amounts are not freely available for dividend
repatriation to the U.S. without the imposition and
payment, where applicable, of local taxes. Further, the
repatriation of these funds is subject to compliance with
applicable local government laws and regulations, and in some
cases, requires governmental consent, including in India and
China. Our inability to repatriate these funds quickly and
without any required governmental consents may limit the
resources available to us to fund our operations in the
U.S. and other locations or to pay indebtedness.
Recently proposed significant changes to the
U.S. international tax laws would limit
U.S. deductions for expenses related to un-repatriated
foreign-source income and modify the U.S. foreign tax
credit and check-the-box rules. We cannot determine
whether these proposals will be enacted into law or what, if
any, changes may be made to such proposals prior to their being
S-10
enacted into law. If the U.S. tax laws change in a manner
that increases our tax obligation, it could result in a material
adverse impact on our net income and our financial position.
Further, because most of our international sales are currently
denominated in U.S. dollars, our products could become less
competitive in international markets if the value of the
U.S. dollar increases relative to foreign currencies. From
time to time, we may enter into foreign currency forward
exchange contracts to minimize risk of loss from currency
exchange rate fluctuations for foreign currency commitments
entered into during the ordinary course of business. We have not
entered into foreign currency forward exchange contracts for
other purposes. As of January 1, 2010, we did not have any
outstanding foreign currency forward exchange contracts. Our
financial condition and results of operations could be affected
(adversely or favorably) by currency fluctuations.
We also conduct a significant portion of our international sales
through distributors. Sales to distributors and other resellers
accounted for approximately 25% of our net revenues in the
fiscal quarters ended January 1, 2010 and January 2,
2009. Sales to distributors and other resellers accounted for
approximately 36%, 34% and 35% of our net revenues in the fiscal
years ended October 2, 2009, October 3, 2008 and
September 28, 2007, respectively. Our arrangements with
these distributors are terminable at any time, and the loss of
these arrangements could have an adverse effect on our operating
results.
We operate in
the highly cyclical semiconductor industry, which is subject to
significant downturns that may negatively impact our business,
financial condition, cash flow and results of
operations.
The semiconductor industry is highly cyclical and is
characterized by constant and rapid technological change, rapid
product obsolescence and price erosion, evolving technical
standards, short product life cycles (for semiconductors and for
the end-user products in which they are used) and wide
fluctuations in product supply and demand. Recent domestic and
global economic conditions have presented unprecedented and
challenging conditions reflecting continued concerns about the
availability and cost of credit, the U.S. mortgage market,
declining real estate values, increased energy costs, decreased
consumer confidence and spending and added concerns fueled by
the U.S. federal governments interventions in the
U.S. financial and credit markets. These conditions have
contributed to instability in both U.S. and international
capital and credit markets and diminished expectations for the
U.S. and global economy. In addition, these conditions make
it extremely difficult for our customers to accurately forecast
and plan future business activities and could cause
U.S. and foreign businesses to slow spending on our
products, which could cause our sales to decrease or result in
an extension of our sales cycles. Further, given uncertainty in
the economic environment, our customers may have difficulties
obtaining capital at adequate or historical levels to finance
their ongoing business and operations, which could impair their
ability to make timely payments to us. If that were to occur, we
may be required to increase our allowance for doubtful accounts
and our days sales outstanding would be negatively impacted. We
cannot predict the timing, strength or duration of any economic
slowdown or subsequent economic recovery, worldwide or within
our industry. If the economy or markets in which we operate
continue to be subject to these adverse economic conditions, our
business, financial condition, cash flow and results of
operations will be adversely affected.
We are subject
to intense competition.
The communications semiconductor industry in general, and the
markets in which we compete in particular, are intensely
competitive. We compete worldwide with a number of U.S. and
international semiconductor providers that are both larger and
smaller than us in terms of resources and market share. We
continually face significant competition in our markets. This
competition results in declining average selling prices for our
products. We also anticipate that additional competitors will
enter our markets as a result of expected growth opportunities,
technological and public policy changes and relatively low
barriers to entry in certain markets of the industry. Many of
our competitors have certain advantages over us, such as
significantly greater sales and marketing, manufacturing,
distribution,
S-11
technical, financial and other resources. In addition, many of
our current and potential competitors have a stronger financial
position, less indebtedness and greater financial resources than
we do. These competitors may be able to devote greater financial
resources to the development, promotion and sale of their
products than we can.
We believe that the principal competitive factors for
semiconductor suppliers in our addressed markets are:
|
|
|
|
|
time-to-market;
|
|
|
|
product quality, reliability and performance;
|
|
|
|
level of integration;
|
|
|
|
price and total system cost;
|
|
|
|
compliance with industry standards;
|
|
|
|
design and engineering capabilities;
|
|
|
|
strategic relationships with customers;
|
|
|
|
customer support;
|
|
|
|
new product innovation; and
|
|
|
|
access to manufacturing capacity.
|
In addition, the financial stability of suppliers is an
important consideration in our customers purchasing
decisions. Our relationship with existing and potential
customers could be adversely affected if our customers perceive
that we lack an appropriate level of financial liquidity or
stability or if they think we are too small to do business with.
Current and potential competitors also have established or may
establish financial or strategic relationships among themselves
or with our existing or potential customers, resellers or other
third parties. These relationships may affect customers
purchasing decisions. Accordingly, it is possible that new
competitors or alliances could emerge and rapidly acquire
significant market share. We cannot assure you that we will be
able to compete successfully against current and potential
competitors.
We own or
lease a significant amount of space in which we do not conduct
operations and doing so exposes us to the financial risks of
default by our tenants and subtenants and expenses related to
carrying vacant property.
As a result of our various reorganization and restructuring
related activities, we lease or own a number of domestic
facilities in which we do not operate. At January 1, 2010,
we had 554,000 square feet of vacant leased space and
456,000 square feet of owned space, of which approximately
89% was being subleased to third parties and 11% was vacant and
offered for sublease. Included in these amounts are
389,000 square feet of owned space in Newport Beach,
California that we have leased to Jazz Semiconductor, Inc. and
126,000 square feet of leased space in Newport Beach,
California that we have subleased to Mindspeed Technologies,
Inc. As of January 1, 2010, the aggregate amount owed to
landlords under space we lease but do not operate over the
remaining terms of the leases was approximately $73 million
and, of this amount, subtenants had lease obligations to us in
the aggregate amount of $10 million. The space we have
subleased to others is, in some cases, at rates less than the
amounts we are required to pay landlords and, of the aggregate
obligations we had to landlords for unused space at
January 1, 2010, approximately $21.0 million was
attributable to space we were attempting to sublease. In the
event one or more of our subtenants fails to make lease payments
to us or otherwise defaults on their obligations to us, we could
incur substantial unanticipated payment obligations to
landlords. In addition, in the event tenants of space we own
fail to make lease payments to us or otherwise default on their
obligations to us, we could be required to
S-12
seek new tenants and we cannot assure you that our efforts to do
so would be successful or that the rates at which we could do so
would be attractive. In the event our estimates regarding our
ability to sublet our available space are incorrect, we would be
required to adjust our restructuring reserves which could have a
material impact on our financial results in the future.
Our revenues,
cash flow from operations and results of operations have
fluctuated in the past and may fluctuate in the future,
particularly given adverse domestic and global economic
conditions.
Our revenues, cash flow and results of operations have
fluctuated in the past and may fluctuate in the future. These
fluctuations are due to a number of factors, many of which are
beyond our control. These factors include, among others:
|
|
|
|
|
changes in end-user demand for the products manufactured and
sold by our customers;
|
|
|
|
the timing of receipt, reduction or cancellation of significant
orders by customers;
|
|
|
|
adverse economic conditions, including the unavailability or
high cost of credit to our customers;
|
|
|
|
the inability of our customers to forecast demand based on
adverse economic conditions;
|
|
|
|
seasonal customer demand;
|
|
|
|
the gain or loss of significant customers;
|
|
|
|
market acceptance of our products and our customers
products;
|
|
|
|
our ability to develop, introduce and market new products and
technologies on a timely basis;
|
|
|
|
the timing and extent of product development costs;
|
|
|
|
new product and technology introductions by competitors;
|
|
|
|
changes in the mix of products we develop and sell;
|
|
|
|
fluctuations in manufacturing yields;
|
|
|
|
availability and cost of products from our suppliers;
|
|
|
|
intellectual property disputes; and
|
|
|
|
the effect of competitive pricing pressures, including decreases
in average selling prices of our products.
|
The foregoing factors are difficult to forecast, and these, as
well as other factors, could materially adversely affect our
business, financial condition, cash flow and results of
operations.
We have
historically incurred substantial losses and may incur
additional future losses.
Our loss from continuing operations for the fiscal years ended
October 2, 2009, October 3, 2008 and
September 28, 2007 was $40.5 million,
$12.7 million, and $179.3 million, respectively. These
results have had a negative impact on our financial condition
and operating cash flows. We cannot assure you that our business
will be profitable or that we will not incur additional
substantial losses in the future. Additional operating losses,
lower than expected product sales or our inability to
restructure our outstanding indebtedness or obtain additional
capital to repay our indebtedness obligations will adversely
affect our cash flow and financial condition and could impair
our ability to satisfy our indebtedness obligations as such
obligations come due.
S-13
Our ability to
use our net operating losses (NOLs) and other tax
attributes to offset future taxable income could be limited by
an ownership change and/or decisions by California and other
states to suspend the use of NOLs.
We have significant NOLs, research and development
(R&D) tax credits, capitalized R&D and
amortizable goodwill available to offset our future
U.S. federal and state taxable income. A significant amount
of our NOLs were acquired in the acquisition of certain of our
subsidiaries. Those NOLs are subject to limitations imposed by
Section 382 of the Internal Revenue Code (and applicable
state law). In addition, our ability to utilize any of our NOLs
and other tax attributes may be subject to significant
limitations under Section 382 of the Internal Revenue Code
(and applicable state law) if we undergo an ownership change. An
ownership change occurs for purposes of Section 382 of the
Internal Revenue Code if, among other things, 5% stockholders
(i.e., stockholders who own or have owned 5% or more of our
stock (with certain groups of less-than-5% stockholders treated
as single stockholders for this purpose)) increase their
aggregate percentage ownership of our common stock by more than
fifty percentage points above the lowest percentage of the stock
owned by these stockholders at any time during the relevant
testing period. An issuance of our common stock in connection
with or as part of an exchange offer for our debt securities or
any other issuance of our common stock can contribute to or
result in an ownership change under Section 382. Stock
ownership for purposes of Section 382 of the Internal
Revenue Code is determined under a complex set of attribution
rules, so that a person is treated as owning stock directly,
indirectly (i.e., through certain entities) and constructively
(through certain related persons and certain unrelated persons
acting as a group). In the event of an ownership change,
Section 382 imposes an annual limitation (based upon our
value at the time of the ownership change, as determined under
Section 382 of the Internal Revenue Code) on the amount of
taxable income a corporation may offset with NOLs. If we undergo
an ownership change, Section 382 would also limit our
ability to use R&D tax credits. In addition, if the tax
basis of our assets exceeded the fair market value of our assets
at the time of the ownership change, Section 382 could also
limit our ability to use amortization of capitalized R&D
and goodwill to offset taxable income for the first five years
following an ownership change. Any unused annual limitation may
be carried over to later years until the applicable expiration
date for the respective NOLs. As a result, our inability to
utilize these NOLs, credits or amortization as a result of any
ownership changes could adversely impact our operating results
and financial condition.
In addition, California and certain states have suspended use of
NOLs for certain taxable years, and other states are considering
similar measures. As a result, we may incur higher state income
tax expense in the future. Depending on our future tax position,
continued suspension of our ability to use NOLs in states in
which we are subject to income tax could have an adverse impact
on our operating results and financial condition.
Our success
depends on our ability to timely develop competitive new
products and reduce costs.
Our operating results depend largely on our ability to introduce
new and enhanced semiconductor products on a timely basis.
Successful product development and introduction depends on
numerous factors, including, among others, our ability to:
|
|
|
|
|
anticipate customer and market requirements and changes in
technology and industry standards;
|
|
|
|
accurately define new products;
|
|
|
|
complete development of new products and bring our products to
market on a timely basis;
|
|
|
|
differentiate our products from offerings of our competitors;
|
|
|
|
achieve overall market acceptance of our products; and
|
|
|
|
coordinate product development efforts between and among our
sites, particularly in India and China, to manage the
development of products at remote geographic locations.
|
S-14
We may not have sufficient resources to make the substantial
investment in research and development in order to develop and
bring to market new and enhanced products, and our recent
reductions in our R&D headcount and other cost savings
initiatives could further hinder our ability to invest in
research and development. We cannot assure you that we will be
able to develop and introduce new or enhanced products in a
timely and cost-effective manner, that our products will satisfy
customer requirements or achieve market acceptance, or that we
will be able to anticipate new industry standards and
technological changes. The complexity of our products may lead
to errors, defects and bugs which could subject us to
significant costs or damages and adversely affect market
acceptance of our products. We also cannot assure you that we
will be able to respond successfully to new product
announcements and introductions by competitors.
In addition, prices of established products may decline,
sometimes significantly and rapidly, over time. We believe that
in order to remain competitive we must continue to reduce the
cost of producing and delivering existing products at the same
time as we develop and introduce new or enhanced products. We
cannot assure you that we will be successful and, as a result,
our gross margins may decline in future periods.
We have
significant goodwill and intangible assets, and future
impairment of our goodwill and intangible assets could have a
material negative impact on our financial condition and results
of operations.
At January 1, 2010, we had $109.9 million of goodwill
and $5.2 million of intangible assets, net, which together
represented approximately 42% of our total assets. In periods
subsequent to an acquisition, at least on an annual basis or
when indicators of impairment exist, we must evaluate goodwill
and acquisition-related intangible assets for impairment. When
such assets are found to be impaired, they will be written down
to estimated fair value, with a charge against earnings. If our
market capitalization drops below our book value for a prolonged
period of time, our assumptions regarding our future operating
performance change or other indicators of impairment are
present, we may be required to write-down the value of our
goodwill and acquisition-related intangible assets by taking a
charge against earnings.
Our remaining goodwill is associated with our business. Goodwill
is tested at the reporting unit level annually in the fourth
fiscal quarter and, if necessary, whenever events or changes in
circumstances indicate that the carrying amount may not be
recoverable. During the fourth fiscal quarter of 2009, we
determined that the fair value of our business was greater than
its carrying value and therefore there was no impairment of
goodwill as of October 2, 2009. There were no indicators of
impairment requiring testing during the fiscal quarter ended
January 1, 2010. Because of the significance of our
remaining goodwill and intangible asset balances, any future
impairment of these assets could have a material adverse effect
on our financial condition and results of operations, although,
as a charge, it would have no effect on our cash flow.
Significant impairments may also impact shareholders
deficit.
The loss of a
key customer could seriously impact our revenue levels and harm
our business. In addition, if we are unable to continue to sell
existing and new products to our key customers in significant
quantities or to attract new significant customers, our future
operating results could be adversely affected.
We have derived a substantial portion of our past revenue from
sales to a relatively small number of customers. As a result,
the loss of any significant customer could materially and
adversely affect our financial condition and results of
operations.
Sales to our 20 largest customers, including distributors,
represented approximately 83% and 68% of our net revenues in the
fiscal quarters ended January 1, 2010 and January 2,
2009, respectively, and approximately 87%, 83% and 82% of our
net revenues in the fiscal years ended October 2, 2009,
October 3, 2008 and September 28, 2007, respectively.
For the fiscal quarters ended January 1, 2010 and
January 2, 2009, one distributor accounted for 15% and 16%,
S-15
respectively, of our net revenues. For each of the fiscal years
ended October 2, 2009, October 3, 2008 and
September 28, 2007, one distributor accounted for 23% of
our net revenues. We expect that our largest customers will
continue to account for a substantial portion of our net revenue
in future periods. The identities of our largest customers and
their respective contributions to our net revenue have varied
and will likely continue to vary from period to period. We may
not be able to maintain or increase sales to certain of our key
customers for a variety of reasons, including the following:
|
|
|
|
|
most of our customers can stop incorporating our products into
their own products with limited notice to us and suffer little
or no penalty;
|
|
|
|
our agreements with our customers typically do not require them
to purchase a minimum quantity of our products;
|
|
|
|
our customers perceptions of our liquidity and viability
may have a negative impact on their decisions to incorporate our
products into their own products;
|
|
|
|
many of our customers have pre-existing or concurrent
relationships with our current or potential competitors that may
affect the customers decisions to purchase our products;
|
|
|
|
our customers face intense competition from other manufacturers
that do not use our products;
|
|
|
|
some of our customers offer or may offer products that compete
with our products;
|
|
|
|
some of our customers liquidity may be negatively affected
by continued uncertainty in global economic conditions; and
|
|
|
|
our small size, our cost-savings efforts and any future
liquidity constraints may limit our ability to develop and
deliver new products to customers.
|
In addition, our longstanding relationships with some larger
customers may also deter other potential customers who compete
with these customers from buying our products. To attract new
customers or retain existing customers, we may offer certain
customers favorable prices on our products. The loss of a key
customer, a reduction in sales to any key customer or our
inability to attract new significant customers could seriously
impact our revenue and materially and adversely affect our
results of operations.
Further, our product portfolio consists predominantly of
semiconductor solutions for the communications, PC, and consumer
markets. Recently, unfavorable domestic and global economic
conditions have had an adverse impact on demand in these
end-user markets by reducing overall consumer spending or
shifting consumer spending to products other than those made by
our customers. Any prolonged or significant decrease in consumer
spending by customers in these end-markets will adversely impact
demand by our customers for our products and could also slow new
product introductions by our customers and by us. Lower net
sales of our products would have an adverse effect on our
revenue, cash flow and results of operations.
We may not be
able to keep abreast of the rapid technological changes in our
markets.
The demand for our products can change quickly and in ways we
may not anticipate because the markets we operate in generally
exhibit the following characteristics:
|
|
|
|
|
rapid technological developments;
|
|
|
|
rapid changes in customer requirements;
|
|
|
|
frequent new product introductions and enhancements;
|
|
|
|
short product life cycles with declining prices over the life
cycle of the products; and
|
|
|
|
evolving industry standards.
|
Our products could become obsolete sooner than anticipated
because of a faster than anticipated change in one or more of
the technologies related to our products or in market demand for
S-16
products based on a particular technology, particularly due to
the introduction of new technology that represents a substantial
advance over current technology. Currently accepted industry
standards are also subject to change, which may contribute to
the obsolescence of our products. Furthermore, as a smaller
company following the sale of our Broadband Access business in
August 2009, we might not be able to fund sufficient research
and development to keep up with technological developments.
We may be
subject to claims of infringement of third-party intellectual
property rights or demands that we license third-party
technology, which could result in significant expense and loss
of our ability to use, make, sell, export or import our products
or one or more components comprising our products.
The semiconductor industry is characterized by vigorous
protection and pursuit of intellectual property rights. From
time to time, third parties have asserted and may in the future
assert patent, copyright, trademark and other intellectual
property rights to technologies that are important to our
business and have demanded and may in the future demand that we
license their patents and technologies. Any litigation to
determine the validity of claims that our products infringe or
may infringe these rights, including claims arising through our
contractual indemnification of our customers, regardless of
their merit or resolution, could be costly and divert the
efforts and attention of our management and technical personnel.
We cannot assure you that we would prevail in litigation given
the complex technical issues and inherent uncertainties in
intellectual property litigation. If litigation results in an
adverse ruling we could be required to:
|
|
|
|
|
pay substantial damages;
|
|
|
|
cease the manufacture, use or sale of infringing products,
processes or technologies;
|
|
|
|
discontinue the use of infringing technology;
|
|
|
|
expend significant resources to develop non-infringing
technology, which we may not be successful in developing; or
|
|
|
|
license technology from the third party claiming infringement,
which license may not be available on commercially reasonable
terms, or at all.
|
If OEMs of
communications electronics products do not design our products
into their equipment, we will be unable to sell those products.
Moreover, a design win from a customer does not guarantee future
sales to that customer.
Our products are components of other products. As a result, we
rely on OEMs of communications electronics products to select
our products from among alternative offerings to be designed
into their equipment. We may be unable to achieve these
design wins. Without design wins from OEMs, we would
be unable to sell our products. Once an OEM designs another
suppliers semiconductors into one of its product
platforms, it will be more difficult for us to achieve future
design wins with that OEMs product platform because
changing suppliers involves significant cost, time, effort and
risk. Achieving a design win with a customer does not ensure
that we will receive significant revenues from that customer and
we may be unable to convert design wins into actual sales. Even
after a design win, the customer is not obligated to purchase
our products and can choose at any time to stop using our
products if, for example, it or its own products are not
commercially successful.
Because of the
lengthy sales cycles of many of our products, we may incur
significant expenses before we generate any revenues related to
those products.
Our customers may need six months or longer to test and evaluate
our products and an additional six months or more to begin
volume production of equipment that incorporates our products.
The lengthy period of time required also increases the
possibility that a customer may decide to cancel or change
product plans, which could reduce or eliminate sales to that
customer. Thus, we may incur significant research and
development, and selling, general and administrative expenses
before we generate the related revenues for these products, and
we may never generate
S-17
the anticipated revenues if our customer cancels or changes its
product plans. As a smaller company following the sale of our
BBA business, exposure to lengthy sales cycles may increase the
volatility of our revenue stream and common stock price.
Uncertainties
involving the ordering and shipment of our products could
adversely affect our business.
Our sales are typically made pursuant to individual purchase
orders and we generally do not have long-term supply
arrangements with our customers. Generally, our customers may
cancel orders until 30 days prior to shipment. In addition,
we sell a portion of our products through distributors and other
resellers, some of whom have a right to return unsold products
to us. Sales to distributors and other resellers accounted for
approximately 25% of our net revenues in the fiscal quarters
ended January 1, 2010 and January 2, 2009. Our
distributors may offer products of several different suppliers,
including products that may be competitive with ours.
Accordingly, there is a risk that the distributors may give
priority to other suppliers products and may not sell our
products as quickly as forecasted, which may impact the
distributors future order levels. We routinely purchase
inventory based on estimates of end-market demand for our
customers products, which is difficult to predict. This
difficulty may be compounded when we sell to OEMs indirectly
through distributors and other resellers or contract
manufacturers, or both, as our forecasts of demand are then
based on estimates provided by multiple parties. In addition,
our customers may change their inventory practices on short
notice for any reason. The cancellation or deferral of product
orders, the return of previously sold products or overproduction
due to the failure of anticipated orders to materialize could
result in our holding excess or obsolete inventory, which could
result in write-downs of inventory.
We are
dependent upon third parties for the manufacture, assembly and
test of our products.
We are entirely dependent upon outside wafer fabrication
facilities (known as foundries or fabs). Therefore, our revenue
growth is dependent on our ability to obtain sufficient external
manufacturing capacity, including wafer fabrication capacity. If
the semiconductor industry experiences a shortage of wafer
fabrication capacity in the future, we risk experiencing delays
in access to key process technologies, production or shipments
and increased manufacturing costs. Moreover, our foundry
partners often require significant amounts of financing in order
to build or expand wafer fabrication facilities. However,
current unfavorable economic conditions have also resulted in a
tightening in the credit markets, decreased the level of
liquidity in many financial markets and resulted in significant
volatility in the credit and equity markets. These conditions
may make it difficult for foundries to obtain adequate or
historical levels of capital to finance the building or
expansion of their wafer fabrication facilities, which would
have an adverse impact on their production capacity and could in
turn negatively impact our wafer output. In addition, certain of
our suppliers have required that we keep in place standby
letters of credit for all or part of the products we order. Such
requirement, or a requirement that we pre-pay for all or part of
vendor invoices or that we shorten our payment cycle times in
the future, may negatively impact our liquidity and cash
position, or may not be available to us due to our then current
liquidity or cash position, and would have a negative impact on
our ability to produce and deliver products to our customers on
a timely basis.
The foundries we use may allocate their limited capacity to
fulfill the production requirements of other customers that are
larger and better financed than us. If we choose to use a new
foundry, it typically takes several months to redesign our
products for the process technology and intellectual property
cores of the new foundry and to complete the qualification
process before we can begin shipping products from the new
foundry.
We are also dependent upon third parties for the assembly and
testing of our products. Our reliance on others to assemble and
test our products subjects us to many of the same risks that we
have with respect to our reliance on outside wafer fabrication
facilities.
Wafer fabrication processes are subject to obsolescence, and
foundries may discontinue a wafer fabrication process used for
certain of our products. In such event, we generally offer our
customers a
S-18
last time buy program to satisfy their anticipated
requirements for our products. The unanticipated discontinuation
of wafer fabrication processes on which we rely may adversely
affect our revenues and our customer relationships.
In the event of a disruption of the operations of one or more of
our suppliers, we may not have a second manufacturing source
immediately available. Such an event could cause significant
delays in shipments until we could shift the products from an
affected facility or supplier to another facility or supplier.
The manufacturing processes we rely on are specialized and are
available from a limited number of suppliers. Alternate sources
of manufacturing capacity, particularly wafer fabrication
capacity, may not be available to us on a timely basis. Even if
alternate wafer fabrication capacity is available, we may not be
able to obtain it on favorable terms, or at all. All such delays
or disruptions could impair our ability to meet our
customers requirements and have a material adverse effect
on our operating results.
In addition, the highly complex and technologically demanding
nature of semiconductor manufacturing has caused foundries from
time to time to experience lower than anticipated manufacturing
yields, particularly in connection with the introduction of new
products and the installation and
start-up of
new process technologies. Lower than anticipated manufacturing
yields may affect our ability to fulfill our customers
demands for our products on a timely basis and may adversely
affect our cost of goods sold and our results of operations.
We may
experience difficulties in transitioning to smaller geometry
process technologies or in achieving higher levels of design
integration, which may result in reduced manufacturing yields,
delays in product deliveries, increased expenses and loss of
design wins to our competitors.
To remain competitive, we expect to continue to transition our
semiconductor products to increasingly smaller line width
geometries. This transition requires us to modify the
manufacturing processes for our products and to redesign some
products, as well as standard cells and other integrated circuit
designs that we may use in multiple products. We periodically
evaluate the benefits, on a
product-by-product
basis, of migrating to smaller geometry process technologies to
reduce our costs. In the past, we have experienced some
difficulties in shifting to smaller geometry process
technologies or new manufacturing processes, which resulted in
reduced manufacturing yields, delays in product deliveries and
increased expenses. We may face similar difficulties, delays and
expenses as we continue to transition our products to smaller
geometry processes. We are dependent on our relationships with
our foundries to transition to smaller geometry processes
successfully. We cannot assure you that our foundries will be
able to effectively manage the transition or that we will be
able to maintain our existing foundry relationships or develop
new ones. If our foundries or we experience significant delays
in this transition or fail to implement this transition
efficiently, we could experience reduced manufacturing yields,
delays in product deliveries and increased expenses, all of
which could negatively affect our relationships with our
customers and result in the loss of design wins to our
competitors, which in turn would adversely affect our results of
operations. As smaller geometry processes become more prevalent,
we expect to continue to integrate greater levels of
functionality, as well as customer and third party intellectual
property, into our products. However, we may not be able to
achieve higher levels of design integration or deliver new
integrated products on a timely basis, or at all. Moreover, even
if we are able to achieve higher levels of design integration,
such integration may have a short-term adverse impact on our
operating results, as we may reduce our revenue by integrating
the functionality of multiple chips into a single chip.
If we are not
successful in protecting our intellectual property rights, it
may harm our ability to compete.
We use a significant amount of intellectual property in our
business. We rely primarily on patent, copyright, trademark and
trade secret laws, as well as nondisclosure and confidentiality
agreements and other methods, to protect our proprietary
technologies and processes. At times, we incorporate
intellectual property licensed from our customers and other
third parties into our designs, and we have obligations with
respect to the non-use and non-disclosure of their intellectual
property. In the past, we
S-19
have engaged in litigation to enforce our intellectual property
rights, to protect our trade secrets or to determine the
validity and scope of proprietary rights of others, including
our customers. We may engage in future litigation on similar
grounds, which may require us to expend significant resources
and to divert the efforts and attention of our management from
our business operations. We cannot assure you that:
|
|
|
|
|
the steps we take to prevent misappropriation or infringement of
our intellectual property or the intellectual property of our
customers will be successful;
|
|
|
|
any existing or future patents will not be challenged,
invalidated or circumvented; or
|
|
|
|
any of the measures described above would provide meaningful
protection.
|
Despite these precautions, it may be possible for a third party
to copy or otherwise obtain and use our technology without
authorization, develop similar technology independently or
design around our patents. If any of our patents fails to
protect our technology, it would make it easier for our
competitors to offer similar products. In addition, effective
patent, copyright, trademark and trade secret protection may be
unavailable or limited in certain countries.
A significant portion of our intellectual property rights is
located in foreign jurisdictions. Because of the differences in
foreign patent, trademark and other laws concerning proprietary
rights, our intellectual property rights frequently do not
receive the same degree of protection in foreign jurisdictions
as they would in the United States. Our failure to obtain or
maintain adequate protection of our intellectual property rights
for any reason could have a material adverse effect on our
business, results of operations and financial condition.
Our success
depends, in part, on our ability to effect suitable investments,
alliances, acquisitions and where appropriate, divestitures and
restructurings.
Although we invest significant resources in research and
development activities, the complexity and speed of
technological changes make it impractical for us to pursue
development of all technological solutions on our own. On an
ongoing basis, we review investment, alliance and acquisition
prospects that would complement our existing product offerings,
augment our market coverage or enhance our technological
capabilities. However, we cannot assure you that we will be able
to identify and consummate suitable investment, alliance or
acquisition transactions in the future.
Moreover, if we consummate such transactions, they could result
in:
|
|
|
|
|
large initial one-time write-offs of in-process research and
development;
|
|
|
|
the incurrence of substantial debt and assumption of unknown
liabilities;
|
|
|
|
the potential loss of key employees from the acquired company;
|
|
|
|
amortization expenses related to intangible assets; and
|
|
|
|
the diversion of managements attention from other business
concerns.
|
Integrating acquired organizations and their products and
services may be expensive, time-consuming and a strain on our
resources and our relationships with employees and customers,
and ultimately may not be successful. The process of integrating
operations could cause an interruption of, or loss of momentum
in, the activities of one or more of our products and the loss
of key personnel. The diversion of managements attention
and any delays or difficulties encountered in connection with
acquisitions and the integration of multiple operations could
have an adverse effect on our business, results of operations or
financial condition.
Moreover, in the event that we have unprofitable operations or
products we may be forced to restructure or divest such
operations or products. There is no guarantee that we will be
able to restructure or divest such operations or products on a
timely basis or at a value that will avoid further
S-20
losses or that will successfully mitigate the negative impact on
our overall operations or financial results.
We may not be
able to attract and retain qualified management, technical and
other personnel necessary for the design, development and sale
of our products. Our success could be negatively affected if key
personnel leave.
Our future success depends on our ability to attract and to
retain the continued service and availability of skilled
personnel at all levels of our business. As the source of our
technological and product innovations, our key technical
personnel represent a significant asset. The competition for
such personnel can be intense. While we have entered into
employment agreements with some of our key personnel, we cannot
assure you that we will be able to attract and retain qualified
management and other personnel necessary for the design,
development and sale of our products.
Litigation
could be costly and harmful to our business.
We are involved in various claims and lawsuits from time to
time. For example, in February 2005, certain of our current and
former officers and our Employee Benefits Plan Committee were
named as defendants in a purported breach of fiduciary duties
class action lawsuit that we recently settled for
$3.25 million. Any of these claims or legal actions could
adversely affect our business, financial position and results of
operations and divert managements attention and resources
from other matters.
We currently
operate under tax holidays and favorable tax incentives in
certain foreign jurisdictions.
While we believe we qualify for these incentives that reduce our
income taxes and operating costs, the incentives require us to
meet specified criteria, which are subject to audit and review.
We cannot assure that we will continue to meet such criteria and
enjoy such tax holidays and incentives. If any of our tax
holidays or incentives are terminated, our results of operations
may be materially and adversely affected.
Risks Related to
Our Common Stock
The price of
our common stock may fluctuate significantly, which may make it
difficult for you to resell your common stock when you want or
at prices you find attractive.
The price of our common stock is volatile and may fluctuate
significantly. For example, since September 29, 2007, the
price of our stock has ranged from a high of $14.80 per share to
a low of $0.26 per share. We cannot assure you as to the prices
at which our common stock will trade or that an active trading
market in our common stock will be sustained in the future. In
addition to the matters discussed in other risk factors included
herein, in the accompanying prospectus and the information
incorporated by reference herein or therein, some of the reasons
for fluctuations in our stock price could include:
|
|
|
|
|
our operating and financial performance and prospects;
|
|
|
|
our ability to repay or restructure our debt;
|
|
|
|
the depth and liquidity of the market for our common stock;
|
|
|
|
investor perception of us and the industry in which we operate;
|
|
|
|
investor perception of us as a going concern and of our ability
to operate successfully as a company with a smaller cash flow
and with significant debt obligations;
|
|
|
|
the level of research coverage of our common stock;
|
|
|
|
changes in earnings estimates or buy/sell recommendations by
analysts;
|
|
|
|
general financial, domestic, international, economic and other
market conditions;
|
S-21
|
|
|
|
|
proposed acquisitions by us or our competitors;
|
|
|
|
the hiring or departure of key personnel; and
|
|
|
|
adverse judgments or settlements obligating us to pay damages.
|
In addition, public stock markets have experienced, and may in
the future experience, extreme price and trading volume
volatility, particularly in the technology sectors of the
market. This volatility has significantly affected the market
prices of securities of many technology companies for reasons
frequently unrelated to or disproportionately impacted by the
operating performance of these companies. These broad market
fluctuations may adversely affect the market price of our common
stock.
If we fail to
continue to meet all applicable continued listing requirements
of the NASDAQ Global Select Market and NASDAQ determines to
delist our common stock, the market liquidity and market price
of our common stock could decline.
Our common stock is listed on the NASDAQ Global Select Market.
In order to maintain that listing, we must satisfy minimum
financial and other continued listing requirements. For example,
NASDAQ rules require that we maintain a minimum bid price of
$1.00 per share for our common stock. Our common stock has in
the past fallen below this minimum bid price requirement and it
may do so again in the future. If our stock price falls below
$1.00 or we fail to meet other requirements for continued
listing on the NASDAQ Global Select Market, and we are unable to
cure the events of noncompliance in a timely or effective
manner, our common stock could be delisted from the NASDAQ
Global Select Market. If appropriate, we may request, as we have
done in the past, approval from our stockholders to implement a
reverse stock split in order to regain compliance with
NASDAQs minimum bid price requirement. If our common stock
were threatened with delisting from the NASDAQ Global Select
Market, we may, depending on the circumstances, seek to extend
the period for regaining compliance with NASDAQ listing
requirements by moving our common stock to the NASDAQ Capital
Market. If our common stock is not eligible for quotation on
another market or exchange, trading of our common stock could be
conducted in the over-the-counter market or on an electronic
bulletin board established for unlisted securities such as the
Pink OTC Markets or the OTC Bulletin Board. In such event,
it could become more difficult to dispose of, or obtain accurate
quotations for the price of, our common stock, and there would
likely also be a reduction in our coverage by security analysts
and the news media, which could cause the price of our common
stock to decline further. In addition, the delisting of our
common stock could give the holders of any outstanding
convertible subordinated notes a right to cause us to repurchase
their convertible subordinated notes and it could result in a
default under the terms and conditions of the indenture
governing our convertible subordinated notes.
Anti-takeover
provisions in our organizational documents and Delaware law
could make it more difficult for a third party to acquire
control of us.
Our restated certificate of incorporation and our bylaws, each
as amended, contain several provisions that would make it more
difficult for a third party to acquire control of us, including:
|
|
|
|
|
a classified board of directors, with three classes of directors
each serving a staggered three-year term;
|
|
|
|
a requirement that a supermajority vote be obtained to remove a
director for cause or to amend or repeal certain provisions of
our restated certificate of incorporation or our bylaws;
|
|
|
|
a prohibition on stockholder action by written consent;
|
|
|
|
a requirement that stockholders provide advance notice of any
stockholder nominations of directors at any meeting of our
stockholders or any proposal of new business to be considered at
an annual meeting of our stockholders;
|
S-22
|
|
|
|
|
the inability of our stockholders to call a special meeting and
a requirement that the only business to be conducted at a
special meeting will be the business brought before the meeting
pursuant to our notice of meeting;
|
|
|
|
the exclusive authority of our board of directors to fill
director vacancies;
|
|
|
|
the ability of our board of directors to issue shares of our
preferred stock in one or more series without further
authorization from our stockholders; and
|
|
|
|
a fair price provision.
|
In addition to the provisions in our restated certificate of
incorporation and our bylaws, Section 203 of the Delaware
General Corporation Law generally provides that a corporation
shall not engage in any business combination with any interested
stockholder during the three-year period following the time that
such stockholder becomes an interested stockholder, unless
either the business combination or the transaction that results
in the stockholder becoming an interested stockholder is
approved in a prescribed manner. These provisions may discourage
certain types of transactions in which our stockholders might
otherwise receive a premium for their shares over the current
market price, and may limit the ability of our stockholders to
approve transactions that they think may be in their best
interests.
We do not
intend to pay cash dividends on our common stock.
We have not paid cash dividends since our inception and do not
intend to pay cash dividends in the foreseeable future. In
addition, we will be prohibited from paying cash dividends under
certain circumstances by the terms of the indenture governing
our senior secured notes. Therefore, stockholders will have to
rely on appreciation in our stock price, if any, in order to
achieve a gain on an investment. There is no guarantee that our
stock will appreciate in value after this offering or even
maintain the price at which you purchased your shares.
There could be
a negative effect on the price of our common stock if we issue
equity securities in connection with a restructuring of any or
all of our outstanding convertible subordinated
notes.
If we decide to issue any equity securities in connection with a
restructuring of any outstanding convertible subordinated notes,
there could be a substantial dilutive effect on our common stock
and an adverse effect on the price of our common stock.
Risks Related to
this Offering
You will
experience immediate dilution in the book value per share of the
common stock you purchase.
Because the price per share of our common stock being offered is
substantially higher than the net tangible book value
(deficiency) per share of our common stock, you will suffer
substantial dilution in the net tangible book value of the
common stock you purchase in this offering. After giving effect
to the sale by us of 14,000,000 shares of common stock in
this offering, and based on the public offering price of $4.00
per share, in this offering and a negative tangible book value
per share of our common stock of $(2.79) as of January 1,
2010, if you purchase shares of common stock in this offering,
you will suffer immediate and substantial dilution of $5.63 per
share in the net tangible book value of the common stock. If the
underwriters exercise their over-allotment option, you will
experience additional dilution. See Dilution on
page S-29
for a more detailed discussion of the dilution you will incur in
connection with this offering.
S-23
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement, the accompanying prospectus and the
documents incorporated by reference herein and therein contain
forward-looking statements within the meaning of
U.S. federal securities laws. Any statements that do not
relate to historical or current facts or matters are
forward-looking statements. You can identify some of the
forward-looking statements by the use of forward-looking words,
including, but not limited to, may,
will, could, project,
believe, anticipate, expect,
estimate, continue,
potential, plan and
forecasts, the negatives of such expressions, or the
use of future tense. Statements concerning current conditions
may also be forward-looking if they imply a continuation of
current conditions. Examples of forward-looking statements
include, but are not limited to, statements concerning:
|
|
|
|
|
our expectations, subject to the qualifications expressed,
regarding the sufficiency of our existing sources of liquidity
and cash to fund our operations, research and development,
anticipated capital expenditures and our working capital needs
for at least the next 12 months and whether we will be able
to repatriate cash from our foreign operations on a timely and
cost-effective basis;
|
|
|
|
our expectation that we will be able to sustain the
recoverability of our goodwill, intangible and tangible
long-term assets;
|
|
|
|
expectations that we will have sufficient capital to repay our
indebtedness as it becomes due and to finance our ongoing
business and operations and that we will be able to successfully
complete restructuring or refinancing alternatives, including
our senior secured notes offering, this common stock offering
and our pending tender offer;
|
|
|
|
expectations that we will be able to use our net operating
losses and other tax attributes to offset future taxable income;
|
|
|
|
expectations regarding the market share of our products, growth
in the markets we serve and our market opportunities;
|
|
|
|
expectations regarding the closing of the sale of our real
property in Newport Beach, California;
|
|
|
|
expectations regarding price and product competition;
|
|
|
|
continued demand and future growth in demand for our products in
the communications, personal computer and consumer markets we
serve;
|
|
|
|
our plans and expectations regarding the transition of our
semiconductor products to smaller line width geometries;
|
|
|
|
our product development plans;
|
|
|
|
our expectation that our largest customers will continue to
account for a substantial portion of our revenue;
|
|
|
|
expectations regarding our contractual obligations and
commitments;
|
|
|
|
our expectation that we will be able to protect our products and
services with proprietary technology and intellectual property
protection;
|
|
|
|
our expectation that we will be able to meet our lease
obligations (and other financial commitments); and
|
|
|
|
our expectation that we will be able to continue to rely on
third party manufacturers to manufacture, assemble and test our
products to meet our customers demands.
|
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ
materially from those expressed in the forward-looking
statements. You are urged to carefully
S-24
review the disclosures we make concerning risks and other
factors that may affect our business and operating results,
including, but not limited to, those factors set forth in the
Risk Factors section and in other sections of this
prospectus supplement and in our most recent Annual Report on
Form 10-K
under the captions Risk Factors,
Business, Legal Proceedings,
Managements Discussion and Analysis of Financial
Condition and Results of Operations, and
Quantitative and Qualitative Disclosures About Market
Risk, our subsequent Quarterly Report on
Form 10-Q
and our other reports filed with the SEC. Please consider our
forward-looking statements in light of those risks as you read
this prospectus supplement and the accompanying prospectus. You
are cautioned not to place undue reliance on these
forward-looking statements, and all forward-looking statements
speak only as of the date on which they are made. Additional
risks relating to our business, the industries in which we
operate or any securities we may offer and sell under this
prospectus may be described from time to time in our filings
with the SEC. We do not intend, and undertake no obligation, to
publish revised forward-looking statements to reflect events or
circumstances after the date of this document or to reflect the
occurrence of unanticipated events.
S-25
USE OF
PROCEEDS
We expect to receive net proceeds of approximately
$52.5 million from the sale of 14,000,000 shares of
our common stock in this offering, or approximately
$60.4 million if the underwriters exercise their
over-allotment option in full, based on the public offering
price of $4.00 per share, and after deducting the underwriting
discounts and commissions and estimated expenses related to this
offering payable by us.
We intend to use the net proceeds from this offering and our
senior secured notes offering, together with available cash on
hand, to repurchase any of the $232.4 million aggregate
principal amount outstanding of our convertible subordinated
notes tendered and accepted for purchase pursuant to our pending
tender offer. This offering, however, is not conditioned upon
the completion of our senior secured notes offering or our
tender offer.
We cannot assure you that we will be successful in consummating
our tender offer, which is conditioned upon the consummation of
our senior secured notes offering and this offering. We cannot
assure you that any of the outstanding convertible subordinated
notes will be tendered pursuant to our tender offer. Any excess
proceeds from this offering will be used for general corporate
purposes, including repurchasing from time to time in the open
market or otherwise, in our sole discretion, any remaining
convertible subordinated notes or redeeming any convertible
subordinated notes that remain outstanding as of March 1,
2011 as soon as practicable after such date, in accordance with
the terms of the indenture governing the convertible
subordinated notes. The convertible subordinated notes bear
interest at a fixed rate of 4.0% per annum and mature on
March 1, 2026. Holders of the convertible subordinated
notes may require us to repurchase, for cash, all or part of
their convertible subordinated notes on March 1, 2011,
March 1, 2016 and March 1, 2021 at a price of 100% of
the principal amount, plus any accrued and unpaid interest. For
a description of the terms of our convertible subordinated
notes, see Managements Discussion and Analysis of
Financial Condition and Results of Operations and the
consolidated financial statements and notes related thereto
incorporated by reference into this prospectus supplement and
the accompanying prospectus.
Pending application of the net proceeds as described above, we
may initially invest the net proceeds in short-term investments,
including investment grade securities.
S-26
CAPITALIZATION
The following table sets forth our cash and cash equivalents and
our total capitalization as of January 1, 2010:
|
|
|
|
|
on an actual basis;
|
|
|
|
on a pro forma basis to give effect to the sale of
14,000,000 shares of common stock by us in this offering at
the public offering price of $4.00 per share, after deducting
the underwriting discounts and commissions and estimated
expenses related to this offering payable by us;
|
|
|
|
on a pro forma basis to give effect to the sale of
14,000,000 shares of common stock by us in this offering at
the public offering price of $4.00 per share, and our senior
secured notes offering, after deducting the underwriting
discounts and commissions for this offering and estimated
expenses related to each offering payable by us; and
|
|
|
|
on a pro forma basis to give effect to the Transactions,
assuming that 14,000,000 shares of common stock are sold by
us in this offering at the public offering price of $4.00 per
share, and assuming that all of the outstanding convertible
subordinated notes are tendered and accepted for purchase
pursuant to our pending tender offer, after deducting the
underwriting discounts and commissions for this offering and
estimated expenses related to the Transactions payable by us.
|
This offering is not conditioned upon the completion of the
tender offer or our senior secured notes offering.
The information in the table below should be read in conjunction
with Summary Summary Consolidated Financial
Information, Use of Proceeds and our
consolidated financial statements and related information
included in or incorporated by reference in this prospectus
supplement and the accompanying prospectus.
S-27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At January 1, 2010
|
|
|
|
|
|
|
|
|
|
Pro forma for
|
|
|
|
|
|
|
|
|
|
|
|
|
this offering and
|
|
|
|
|
|
|
|
|
|
Pro forma for
|
|
|
the senior secured
|
|
|
Pro forma for
|
|
|
|
Actual
|
|
|
this offering
|
|
|
notes offering
|
|
|
the Transactions(1)
|
|
|
|
(unaudited)
|
|
|
|
(In thousands, except for share and par value amounts)
|
|
|
Cash and cash equivalents
|
|
$
|
59,084
|
|
|
$
|
111,557
|
|
|
$
|
279,345
|
|
|
$
|
42,064
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt (including current portion):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.00% convertible subordinated notes due March 2026, net of debt
discount of $16,468(2)
|
|
|
215,902
|
|
|
|
215,902
|
|
|
|
215,902
|
|
|
|
|
|
Senior secured notes, net of discount of $1,640
|
|
|
|
|
|
|
|
|
|
|
173,360
|
|
|
|
173,360
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-term debt
|
|
|
215,902
|
|
|
|
215,902
|
|
|
|
389,262
|
|
|
|
173,360
|
|
Shareholders deficit:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred and junior preferred stock, 20,000,000 and
5,000,000 shares authorized, respectively
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par value, 100,000,000 shares
authorized, 65,051,404 and 79,051,404 pro forma shares issued
and outstanding at January 1, 2010
|
|
|
651
|
|
|
|
791
|
|
|
|
791
|
|
|
|
791
|
|
Additional paid-in capital
|
|
|
4,854,511
|
|
|
|
4,906,844
|
|
|
|
4,906,844
|
|
|
|
4,906,844
|
|
Accumulated deficit
|
|
|
(4,921,409
|
)
|
|
|
(4,921,409
|
)
|
|
|
(4,921,409
|
)
|
|
|
(4,921,409
|
)
|
Accumulated other comprehensive loss
|
|
|
(403
|
)
|
|
|
(403
|
)
|
|
|
(403
|
)
|
|
|
(403
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders deficit
|
|
|
(66,650
|
)
|
|
|
(14,177
|
)
|
|
|
(14,177
|
)
|
|
|
(14,177
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total capitalization
|
|
$
|
149,252
|
|
|
$
|
201,725
|
|
|
$
|
375,085
|
|
|
$
|
159,183
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
We cannot assure you that any of the outstanding convertible
subordinated notes will be tendered pursuant to our pending
tender offer. For each $23.2 million aggregate principal
amount of outstanding convertible subordinated notes not
tendered and accepted for purchase pursuant to the tender offer,
at January 1, 2010, our cash and cash equivalents would
have increased by $23.5 million, our total long-term debt
would have increased by $21.6 million, net of debt discount
of $1.6 million, and our total capitalization would have
increased by $21.6 million. |
|
(2) |
|
We have commenced an offer to purchase the outstanding
convertible subordinated notes at par. The tender offer is
scheduled to expire on March 30, 2010, unless extended by
us. |
S-28
DILUTION
The net tangible book value (deficiency) of our common stock on
January 1, 2010 was $(181.7) million, or $(2.79) per
share of common stock. Net tangible book value (deficiency) per
share is calculated by subtracting our total liabilities from
our total tangible assets, which is total assets less goodwill
of $109.9 million and intangible assets of
$5.2 million, and dividing this amount by the number of
shares of our common stock outstanding on January 1, 2010.
After giving effect to the sale by us of 14,000,000 shares
of common stock in this offering at the public offering price of
$4.00 per share, after deducting the underwriting discounts and
commissions and estimated expenses related to this offering
payable by us, our adjusted net tangible book value (deficiency)
as of January 1, 2010 would have been $(129.2), or $(1.63)
per share of our common stock. This represents an immediate
increase in net tangible book value of $1.16 per share to our
existing stockholders and an immediate decrease in the net
tangible book value of $5.63 per share to new investors.
Dilution in the net tangible book value per share represents the
difference between the offering price per share and the net
tangible book value per share of our common stock immediately
after this offering. The following table illustrates this per
share dilution:
|
|
|
|
|
|
|
|
|
Public offering price per common share
|
|
|
|
|
|
$
|
4.00
|
|
Net tangible book value (deficiency) per common share as of
January 1, 2010
|
|
$
|
(2.79
|
)
|
|
|
|
|
Increase per share attributable to this offering
|
|
|
1.16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net tangible book value (deficiency) per common share after
giving effect to this offering
|
|
|
|
|
|
|
(1.63
|
)
|
|
|
|
|
|
|
|
|
|
Dilution per common share to new investors
|
|
|
|
|
|
$
|
5.63
|
|
|
|
|
|
|
|
|
|
|
If the underwriters exercise their over-allotment option to
purchase additional shares in full in this offering at the
public offering price of $4.00 per share, the adjusted net
tangible book value (deficiency) as of January 1, 2010
after giving effect to this offering would decrease to $(1.53)
per share, and dilution per share to new investors in this
offering would be $5.53 per share.
S-29
UNDERWRITING
We have entered into an underwriting agreement with the
underwriters named below with respect to the shares being
offered. Subject to certain conditions, each underwriter has
severally agreed to purchase the number of shares indicated in
the following table. Goldman, Sachs & Co. is the
representative of the underwriters.
|
|
|
|
|
Underwriters
|
|
Number of Shares
|
|
|
Goldman, Sachs & Co.
|
|
|
12,600,000
|
|
Oppenheimer & Co. Inc.
|
|
|
1,400,000
|
|
|
|
|
|
|
Total
|
|
|
14,000,000
|
|
|
|
|
|
|
The underwriters are committed to take and pay for all of the
shares being offered, if any are taken, other than the shares
covered by the option described below unless and until this
option is exercised.
If the underwriters sell more shares than the total number set
forth in the table above, the underwriters have an option to buy
up to an additional 2,100,000 shares from us. They may
exercise that option for 30 days. If any shares are
purchased pursuant to the option, the underwriters will
severally purchase shares in approximately the same proportion
as set forth in the table above.
The following table shows the per share and total underwriting
discounts and commissions to be paid to the underwriters by us.
Such amounts are shown assuming both no exercise and full
exercise of the underwriters option to purchase 2,100,000
additional shares.
|
|
|
|
|
|
|
|
|
|
|
No Exercise
|
|
Full Exercise
|
|
Per Share
|
|
$
|
0.22
|
|
|
$
|
0.22
|
|
Total
|
|
$
|
3,080,000
|
|
|
$
|
3,542,000
|
|
Shares sold by the underwriters to the public will initially be
offered at the initial public offering price set forth on the
cover of this prospectus supplement. Any shares sold by the
underwriters to securities dealers may be sold at a discount of
up to $0.132 per share from the initial public offering
price. If all of the shares are not sold at the initial public
offering price, the representative may change the offering price
and the other selling terms. The offering of the shares by the
underwriters is subject to receipt and acceptance and subject to
the underwriters right to reject any order in whole or in
part.
We and our directors and executive officers have agreed with the
underwriters, subject to certain exceptions, not to dispose of
or hedge any of their common stock or securities convertible
into or exchangeable for shares of common stock during the
period from the date of this prospectus supplement continuing
through the date that is 90 days after the date of this
prospectus supplement, except with the prior written consent of
the representative.
In connection with this offering, the underwriters may purchase
and sell shares of common stock in the open market. These
transactions may include short sales, stabilizing transactions
and purchases to cover positions created by short sales. Shorts
sales involve the sale by the underwriters of a greater number
of shares than they are required to purchase in this offering.
Covered short sales are sales made in an amount not
greater than the underwriters option to purchase
additional shares from us in this offering. The underwriters may
close out any covered short position by either exercising their
option to purchase additional shares or purchasing shares in the
open market. In determining the source of shares to close out
the covered short position, the underwriters will consider,
among other things, the price of shares available for purchase
in the open market as compared to the price at which they may
purchase additional shares pursuant to the option granted to
them. Naked short sales are any sales in excess of
such option. The underwriters must close out any naked short
position by purchasing shares in the open market. A naked short
position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of
the common stock in the open market after pricing that could
adversely affect investors who
S-30
purchase in this offering. Stabilizing transactions consist of
various bids for or purchases of common stock made by the
underwriters in the open market prior to the completion of this
offering.
The underwriters may also impose a penalty bid, which occurs
when a particular underwriter repays to the underwriters a
portion of the underwriting discount received by it because the
representative has repurchased shares sold by or for the account
of such underwriter in stabilizing or short covering
transactions.
Purchases to cover a short position and stabilizing
transactions, as well as other purchases by the underwriters for
their own account, may have the effect of preventing or
retarding a decline in the market price of our common stock, and
together with the imposition of the penalty bid, may stabilize,
maintain or otherwise affect the market price of the common
stock. As a result, the price of our common stock may be higher
than the price that otherwise might exist in the open market. If
these activities are commenced, they may be discontinued at any
time. These transactions may be effected on the NASDAQ, in the
over-the-counter
market or otherwise.
We may enter into derivative transactions with third parties, or
sell securities not covered by this prospectus supplement to
third parties in privately negotiated transactions. In
connection with those derivatives, the third parties may sell
securities covered by this prospectus supplement, including in
short sale transactions. If so, the third party may use
securities pledged by us or borrowed from us or others to settle
those sales or to close out any related open borrowings of
stock, and may use securities received from us in settlement of
those derivatives to close out any related open borrowings of
stock. The third party in such sale transactions will be an
underwriter or will be identified in a post-effective amendment.
Foreign Selling
Restrictions
European Economic
Area
In relation to each Member State of the European Economic Area
which has implemented the Prospectus Directive (each, a
Relevant Member State), each underwriter has
represented and agreed that, with effect from and including the
date on which the Prospectus Directive is implemented in that
Relevant Member State (the Relevant Implementation
Date) it has not made and will not make an offer of shares
to the public in that Relevant Member State prior to the
publication of a prospectus in relation to the shares which has
been approved by the competent authority in that Relevant Member
State or, where appropriate, approved in another Relevant Member
State and notified to the competent authority in that Relevant
Member State, all in accordance with the Prospectus Directive,
except that it may, with effect from and including the Relevant
Implementation Date, make an offer of shares to the public in
that Relevant Member State at any time:
|
|
|
|
(a)
|
to legal entities which are authorised or regulated to operate
in the financial markets or, if not so authorised or regulated,
whose corporate purpose is solely to invest in securities;
|
|
|
(b)
|
to any legal entity which has two or more of (1) an average
of at least 250 employees during the last financial year;
(2) a total balance sheet of more than 43,000,000 and
(3) an annual net turnover of more than 50,000,000,
as shown in its last annual or consolidated accounts;
|
|
|
(c)
|
to fewer than 100 natural or legal persons (other than qualified
investors as defined in the Prospectus Directive) subject to
obtaining the prior consent of the representatives for any such
offer; or
|
|
|
(d)
|
in any other circumstances which do not require the publication
by us of a prospectus pursuant to Article 3 of the
Prospectus Directive.
|
For the purposes of this provision, the expression an
offer of shares to the public in relation to any
shares in any Relevant Member State means the communication in
any form and by any means of sufficient information on the terms
of this offering and the shares to be offered so as to enable an
investor to decide to purchase or subscribe for the shares, as
the same may be varied in that
S-31
Relevant Member State by any measure implementing the Prospectus
Directive in that Relevant Member State and the expression
Prospectus Directive means Directive 2003/71/EC and includes any
relevant implementing measure in each Relevant Member State.
United
Kingdom
Each underwriter has represented and agreed that:
|
|
|
|
(a)
|
it has only communicated or caused to be communicated and will
only communicate or cause to be communicated an invitation or
inducement to engage in investment activity (within the meaning
of Section 21 of the Financial Services and Markets Act
(FSMA)) received by it in connection with the issue
or sale of the shares in circumstances in which
Section 21(1) of the FSMA does not apply to the
Issuer; and
|
|
|
(b)
|
it has complied and will comply with all applicable provisions
of the FSMA with respect to anything done by it in relation to
the shares in, from or otherwise involving the United Kingdom.
|
Hong
Kong
The shares may not be offered or sold by means of any document
other than (i) in circumstances which do not constitute an
offer to the public within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), or (ii) to
professional investors within the meaning of the
Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
and any rules made thereunder, or (iii) in other
circumstances which do not result in the document being a
prospectus within the meaning of the Companies
Ordinance (Cap.32, Laws of Hong Kong), and no advertisement,
invitation or document relating to the shares may be issued or
may be in the possession of any person for the purpose of issue
(in each case whether in Hong Kong or elsewhere), which is
directed at, or the contents of which are likely to be accessed
or read by, the public in Hong Kong (except if permitted to do
so under the laws of Hong Kong) other than with respect to
shares which are or are intended to be disposed of only to
persons outside Hong Kong or only to professional
investors within the meaning of the Securities and Futures
Ordinance (Cap. 571, Laws of Hong Kong) and any rules made
thereunder.
Singapore
This prospectus supplement has not been registered as a
prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus supplement and any other document
or material in connection with the offer or sale, or invitation
for subscription or purchase, of the shares may not be
circulated or distributed, nor may the shares be offered or
sold, or be made the subject of an invitation for subscription
or purchase, whether directly or indirectly, to persons in
Singapore other than (i) to an institutional investor under
Section 274 of the Securities and Futures Act,
Chapter 289 of Singapore (the SFA),
(ii) to a relevant person, or any person pursuant to
Section 275(1A), and in accordance with the conditions,
specified in Section 275 of the SFA or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA.
Where the shares are subscribed or purchased under
Section 275 by a relevant person which is: (a) a
corporation (which is not an accredited investor) the sole
business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of
whom is an accredited investor; or (b) a trust (where the
trustee is not an accredited investor) whose sole purpose is to
hold investments and each beneficiary of which is an accredited
investor, shares, debentures and units of shares and debentures
of that corporation or the beneficiaries rights and
interest in that trust shall not be transferable for
6 months after that corporation or that trust has acquired
the shares under Section 275 except: (1) to an
institutional investor under Section 274 of the SFA or to a
relevant person, or any person pursuant to Section 275(1A),
and in accordance with the
S-32
conditions, specified in Section 275 of the SFA;
(2) where no consideration is given for the transfer; or
(3) by operation of law.
Japan
The securities have not been and will not be registered under
the Financial Instruments and Exchange Law of Japan (the
Financial Instruments and Exchange Law) and each underwriter has
agreed that it will not offer or sell any securities, directly
or indirectly, in Japan or to, or for the benefit of, any
resident of Japan (which term as used herein means any person
resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering
or resale, directly or indirectly, in Japan or to a resident of
Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Law and any other applicable laws,
regulations and ministerial guidelines of Japan.
We estimate that our share of the total expenses of this
offering, excluding underwriting discounts and commissions, will
be approximately $450,000.
We have agreed to indemnify the several underwriters against
certain liabilities, including liabilities under the Securities
Act.
The underwriters and their respective affiliates are full
service financial institutions engaged in various activities,
which may include securities trading, commercial and investment
banking, financial advisory, investment management, principal
investment, hedging, financing and brokerage activities. Certain
of the underwriters and their respective affiliates have, from
time to time, performed, and may in the future perform, various
financial advisory and investment banking services for us and
our affiliates, for which they received or will receive
customary fees and expenses. The representative is acting as
initial purchaser in connection with our senior secured notes
offering and as dealer manager in connection with our tender
offer and, in each case, is expected to receive customary fees
and expense reimbursements in connection therewith.
In the ordinary course of their various business activities, the
underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial
instruments (including bank loans) for their own account and for
the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such
investment and securities activities may involve our securities
and instruments.
S-33
MATERIAL U.S.
FEDERAL INCOME TAX CONSEQUENCES FOR
NON-U.S.
HOLDERS OF COMMON STOCK
The following is a general discussion of the material
U.S. federal income tax consequences relating to the
ownership and disposition of our common stock by
non-U.S. holders
(as defined below) who purchase our common stock in this
offering and hold such common stock as capital assets (generally
for investment). This discussion is based on currently existing
provisions of the Internal Revenue Code of 1986, as amended,
applicable U.S. Treasury regulations promulgated
thereunder, judicial decisions, and rulings and pronouncements
of the U.S. Internal Revenue Service, or the IRS, all as in
effect on the date hereof and all of which are subject to
change, possibly with retroactive effect, or subject to
different interpretation. This discussion does not address all
the tax consequences that may be relevant to specific holders in
light of their particular circumstances or to holders subject to
special treatment under U.S. federal income or estate tax
laws (such as financial institutions, insurance companies,
tax-exempt organizations, controlled foreign corporations,
passive foreign investment companies, retirement plans,
partnerships and their partners, dealers in securities, brokers,
U.S. expatriates, persons who have acquired our common
stock as compensation or otherwise in connection with the
performance of services, or persons who have acquired our common
stock as part of a straddle, hedge, conversion transaction or
other integrated investment). This discussion does not address
the state, local or
non-U.S. tax
or U.S. federal alternative minimum or estate tax
consequences relating to the ownership and disposition of our
common stock. You are urged to consult your own tax advisor
regarding the U.S. federal tax consequences of owning and
disposing of our common stock, as well as the applicability and
effect of any state, local or
non-U.S. tax
laws.
As used in this discussion, the term
non-U.S. holder
refers to a beneficial owner of our common stock that for
U.S. federal income tax purposes is not:
(i) an individual who is a citizen or resident of the
United States;
(ii) a corporation (or other entity taxable as a
corporation) created or organized in or under the laws of the
United States or any state thereof, including the District of
Columbia;
(iii) an estate the income of which is subject to
U.S. federal income tax regardless of the source
thereof; or
(iv) a trust (a) with respect to which a court within
the United States is able to exercise primary supervision over
its administration and one or more U.S. persons have the
authority to control all its substantial decisions, or
(b) that has in effect a valid election under applicable
Treasury regulations to be treated as a U.S. person.
An individual may be treated as a resident of the United States,
among other ways, if present in the United States on at least
31 days in a calendar year and for an aggregate of at least
183 days during the three-year period ending in that
calendar year (counting for such purposes all the days present
in the current year, one-third of the days present in the
immediately preceding year and one-sixth of the days present in
the second preceding year). U.S. residents are subject to
U.S. federal income tax in the same manner as
U.S. citizens.
If a partnership or other entity or arrangement treated as a
partnership for U.S. federal income tax purposes holds our
common stock, the tax treatment of a partner will generally
depend upon the status of the partner and the activities of the
partnership. If you are a partner of a partnership holding our
common stock, we urge you to consult your own tax advisor.
Dividends
We do not anticipate paying dividends on our common stock in the
foreseeable future. See We do not intend to pay cash
dividends on our common stock under the heading
Risk Factors Risks Related to our Common
Stock. Distributions paid by us to a
non-U.S. holder
with respect to our
S-34
common stock, to the extent treated as dividends for
U.S. federal income tax purposes, generally will be subject
to U.S. federal withholding tax at a 30% rate, unless
(i) an applicable income tax treaty reduces or eliminates
such tax, and a
non-U.S. holder
provides us with an IRS
Form W-8BEN
(or successor form) certifying its entitlement to the benefit of
such treaty, or (ii) the dividends are effectively
connected with a
non-U.S. holders
conduct of a trade or business in the United States and the
non-U.S. holder
provides us with an IRS
Form W-8ECI
(or successor form). In the latter case, a
non-U.S. holder
generally will be subject to U.S. federal income tax with
respect to such dividends in the same manner as a
U.S. person, unless otherwise provided in an applicable
income tax treaty. Additionally, a
non-U.S. holder
that is a corporation may be subject to a branch profits tax on
its after-tax effectively connected dividend income at a rate of
30% (or at a reduced rate under an applicable income tax
treaty). If a
non-U.S. holder
is eligible for a reduced rate of U.S. federal withholding
tax pursuant to an income tax treaty, such
non-U.S. holder
may obtain a refund of any excess amount withheld by filing an
appropriate claim for refund with the IRS.
Sale, Exchange or
Other Disposition
Generally, a
non-U.S. holder
will not be subject to U.S. federal income tax on gain
realized upon the sale, exchange or other disposition of our
common stock unless (i) such
non-U.S. holder
is an individual present in the U.S. for 183 days or
more in the taxable year of the sale, exchange or other
disposition and certain other conditions are met, (ii) the
gain is effectively connected with such
non-U.S. holders
conduct of a trade or business in the United States and, where a
tax treaty so provides, the gain is attributable to a
U.S. permanent establishment or fixed base of such
non-U.S. holder,
or (iii) we are or have been a U.S. real
property holding corporation for U.S. federal income
tax purposes at any time during the shorter of the five-year
period ending on the date of disposition or the period that the
non-U.S. holder
held our common stock and either (a) our common stock has
ceased to be traded on an established securities
market prior to the beginning of the calendar year in
which the sale, exchange or other disposition occurs, or
(b) the
non-U.S. holder
owns (actually or constructively) more than five percent of our
common stock. An individual
non-U.S. holder
who is subject to U.S. federal income tax because the
non-U.S. holder
was present in the U.S. for 183 days or more during
the taxable year of sale, exchange or other disposition of our
common stock will be subject to a flat 30% tax on the gain
derived from such sale or other disposition, which may be offset
by United States source capital losses realized in such year.
Gain that is effectively connected with the
non-U.S. holders
conduct of a trade or business in the United States and, where a
tax treaty so provides, the gain is attributable to a
U.S. permanent establishment or fixed base, generally will
be subject to U.S. federal income tax, net of certain
deductions, at regular U.S. federal income tax rates. If
the
non-U.S. holder
is a foreign corporation, the branch profits tax described above
also may apply to such effectively connected gain. We believe
that we are not a U.S. real property holding corporation,
and we do not anticipate becoming a U.S. real property
holding corporation.
Information
Reporting and Backup Withholding Tax
Information reporting and backup withholding tax (at the then
applicable rate) may apply to certain payments made to a
non-U.S. holder
on or with respect to our common stock, unless the
non-U.S. holder
certifies as to its status as a
non-U.S. holder
under penalties of perjury or otherwise establishes an exemption
and certain other conditions are satisfied. Backup withholding
is not an additional tax. Any amounts withheld under the backup
withholding rules from a payment to a
non-U.S. holder
will be allowed as a refund or a credit against such
non-U.S. holders
U.S. federal income tax liability, provided that the
required information is timely furnished to the IRS and other
applicable requirements are satisfied.
Proposed
Legislation Relating to Foreign Accounts
Legislation has been introduced into the U.S. Congress that
would impose withholding taxes on certain types of payments made
to foreign financial institutions and certain other
non-U.S. entities,
S-35
unless certain certification and reporting requirements are
satisfied. A substantially similar proposal was also included as
part of President Obamas proposed budget plan for fiscal
year 2011. If this legislation or other similar legislation is
enacted, the failure to comply with additional certification,
information reporting and other specified requirements could
result in withholding tax being imposed on payments of dividends
and sales proceeds to foreign intermediaries and certain
non-U.S. holders.
Any such legislation could substantially change some of the
rules discussed above relating to certification requirements,
information reporting and withholding. The U.S. House of
Representatives and the U.S. Senate have each passed, as
parts of different bills, a version of this legislation that
would apply to payments made after December 31, 2012. No
assurances can be given whether, or in what form, this
legislation will be enacted. Prospective investors should
consult their own tax advisors regarding this legislation and
similar proposals.
LEGAL
MATTERS
The validity of the shares of common stock offered hereby will
be passed upon for us by OMelveny & Myers LLP.
Certain legal matters in connection with this offering will be
passed upon for the underwriters by Latham & Watkins
LLP, New York, New York.
EXPERTS
The consolidated financial statements, and the related financial
statement schedule, incorporated in this prospectus supplement
by reference from the Companys Annual Report on
Form 10-K
for the year ended October 2, 2009, as subsequently
amended, which report was reissued and included in a Current
Report on
Form 8-K
filed by the Company on February 8, 2010, and the
effectiveness of Conexant Systems, Inc.s internal control
over financial reporting have been audited by
Deloitte & Touche LLP, an independent registered
public accounting firm, as stated in their reports, which are
incorporated herein by reference. Such consolidated financial
statements and financial statement schedule have been so
incorporated in reliance upon the reports of such firm given
upon their authority as experts in accounting and auditing.
WHERE YOU CAN
FIND MORE INFORMATION
We file annual, quarterly and current reports and other
information with the SEC. You may read and copy materials that
we have filed with the SEC at the SECs Public Reference
Room at 100 F Street, N.E., Washington, D.C.
20549. You can request copies of these documents by writing to
the SEC and paying a fee for the copying cost. Please call the
SEC at
1-800-SEC-0330
for further information about the public reference room. The SEC
also maintains an Internet website at www.sec.gov that
contains our annual, quarterly and current reports and other
information that we file electronically with the SEC. Our recent
SEC filings are also available to the public free of charge at
our website at www.conexant.com. Information on or
accessible through our website is not included or incorporated
into this prospectus supplement or the accompanying prospectus.
This prospectus supplement and the accompanying prospectus are
only part of a registration statement on
Form S-3
that we have filed with the SEC under the Securities Act of
1933, as amended, and therefore omit certain information
contained in the registration statement. We have also filed
exhibits and schedules with the registration statement that are
excluded from this prospectus supplement and the accompanying
prospectus, and you should refer to the applicable exhibit or
schedule for a complete description of any statement referring
to any contract or other document. Statements relating to such
documents are qualified in all aspects by such reference.
S-36
INCORPORATION OF
CERTAIN DOCUMENTS BY REFERENCE
We incorporate by reference certain information we
file with the SEC into this prospectus supplement and the
accompanying prospectus. This means that we can disclose
important information to you by referring you to those
documents. The information in the documents incorporated herein
by reference is considered to be part of this prospectus
supplement and the accompanying prospectus, and information in
documents that we file later with the SEC will automatically
update and supersede this information. We incorporate by
reference our documents listed below and filed pursuant to the
Exchange Act:
|
|
|
|
|
Annual Report on
Form 10-K
for the fiscal year ended October 2, 2009 (filed on
November 27, 2009), as amended by Amendment No. 1 on
Form 10-K/A
(filed on December 22, 2009) (including those portions of
our Definitive Proxy Statement on Schedule 14A, filed with
the SEC on January 8, 2010, that are incorporated by
reference into Part III of such Annual Report on
Form 10-K);
|
|
|
|
Quarterly Report on
Form 10-Q
for the fiscal quarter ended January 1, 2010 (filed on
February 8, 2010);
|
|
|
|
Current Reports on
Form 8-K
filed on October 14, 2009, November 3, 2009,
November 13, 2009, November 18, 2009,
November 20, 2009, November 23, 2009, December 3,
2009, December 11, 2009, December 24, 2009 (with
respect to Items 1.01, 5.03 and 8.01 and Exhibits 3.2
and 99.2 of Item 9.01 only), January 19, 2010,
February 8, 2010 (two reports), February 22, 2010,
February 24, 2010 and March 3, 2010 (with respect to
Item 8.01 and Exhibit 99.2 of Item 9.01 only); and
|
|
|
|
The description of our common stock contained in Item 11 of
our Registration Statement on Form 10, as amended,
including any amendment or report filed that updates such
description.
|
All documents filed by us pursuant to Section 13(a), 13(c),
14 or 15(d) of the Exchange Act subsequent to the date of this
prospectus supplement and until the termination or completion of
this offering shall be deemed incorporated by reference into
this prospectus supplement and the accompanying prospectus by
reference (except that, unless otherwise indicated in the
applicable report, we are not incorporating any information
furnished under Item 2.02 or Item 7.01 of
Form 8-K).
Any statement contained in a document incorporated or deemed to
be incorporated by reference in this prospectus supplement or
the accompanying prospectus shall be deemed to be modified or
superseded for purposes of this prospectus supplement and the
accompanying prospectus to the extent that a statement contained
herein or therein or in any other subsequently filed document
which also is incorporated or deemed to be incorporated by
reference herein or therein modifies or supersedes such
statement. Any such statement so modified or superseded shall
not be deemed, except as so modified or superseded, to
constitute a part of this prospectus supplement or the
accompanying prospectus. You may request a free copy of these
filings by writing to us at the following address or calling us
at
(949) 483-4600:
4000 MacArthur Boulevard, Newport Beach, California
92660-3095,
Attention: Secretary.
S-37
PROSPECTUS
$100,000,000
CONEXANT SYSTEMS,
INC.
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
We may offer, from time to time, in one or more series:
|
|
|
|
|
shares of our common stock;
|
|
|
|
shares of our preferred stock;
|
|
|
|
senior
and/or
subordinated debt securities;
|
|
|
|
warrants to purchase common stock, preferred stock
and/or debt
securities; and
|
|
|
|
units consisting of two or more of these classes or series of
securities.
|
We may sell any combination of these securities in one or more
offerings, up to an aggregate offering price of $100,000,000, on
terms to be determined at the time of offering.
This prospectus provides you with a general description of the
securities that we may offer and sell from time to time. Each
time we sell securities, we will provide a prospectus supplement
that will contain specific information about the terms of the
securities offered and may also add, update or change the
information in this prospectus. You should read this prospectus
and the applicable prospectus supplement carefully before you
invest in our securities.
We may offer and sell these securities directly to you, through
agents we select or through underwriters or dealers we select.
If any agent, dealer or underwriter is involved in the sale of
our securities, we will name them and describe their
compensation in a prospectus supplement.
Our shares of common stock are quoted on the Nasdaq Global
Select Market under the symbol CNXT. On
January 14, 2010 the closing sale price of our common
stock, as reported on the Nasdaq Global Select Market, was $3.00
per share. As of the date of this prospectus, none of the other
securities that we may offer by this prospectus are listed on
any national securities exchange or automated quotation system.
Investing in our securities involves a high degree of risk.
See Risk Factors on page 4.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal
offense.
This prospectus may not be used to sell securities unless
accompanied by the applicable prospectus supplement.
The date of this prospectus is January 25, 2010.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
1
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
4
|
|
|
|
|
5
|
|
|
|
|
8
|
|
|
|
|
18
|
|
|
|
|
19
|
|
|
|
|
20
|
|
|
|
|
21
|
|
|
|
|
21
|
|
You should rely only on the information contained or
incorporated by reference in this prospectus and in any
prospectus supplement accompanying this prospectus and that we
have referred you to. No dealer, salesperson or other person is
authorized to give information that is different. This
prospectus is not an offer to sell nor is it seeking an offer to
buy these securities in any jurisdiction where the offer or sale
is not permitted. The information contained in this prospectus
or in any prospectus supplement is correct only as of the date
on the front of those documents, regardless of the time of the
delivery of this prospectus or any prospectus supplement or any
sale of these securities.
ABOUT THIS
PROSPECTUS
This prospectus is part of a registration statement on
Form S-3
that we filed with the Securities and Exchange Commission, or
SEC, utilizing a shelf registration process. Under the shelf
registration process, we may offer common stock, preferred
stock, debt securities, warrants or units from time to time in
one or more offerings up to a total public offering price of
$100,000,000.
This prospectus provides you with a general description of the
securities we may offer. If required, each time securities are
offered under this prospectus, we will provide a prospectus
supplement that will contain specific information about the
terms of that offering and those securities. A prospectus
supplement may include a discussion of risks or other special
considerations applicable to us or the offered securities. A
prospectus supplement may also add, update or change information
in this prospectus. If there is any inconsistency between the
information in this prospectus and the applicable prospectus
supplement, you must rely on the information in the prospectus
supplement. Please carefully read both this prospectus and the
applicable prospectus supplement together with additional
information described under the heading Where You Can Find
More Information.
WHERE YOU CAN
FIND MORE INFORMATION
We have filed with the SEC a registration statement on
Form S-3
under the Securities Act of 1933, as amended, or the Securities
Act, with respect to the securities offered by this prospectus.
As permitted by the SECs rules, this prospectus does not
contain all the information set forth in the registration
statement and the exhibits and schedules thereto. For further
information about us and the securities, we refer you to the
registration statement and to the exhibits and schedules filed
with it. Statements contained in this prospectus as to the
contents of any contract or other documents referred to are not
necessarily complete. We refer you to those copies of contracts
or other documents that have been filed as exhibits to the
registration statement, and statements relating to such
documents are qualified in all aspects by such reference.
We file reports with the SEC on a regular basis that contain
financial information and results of operations. You may read
and copy any document that we file with the SEC at the
SECs Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. You may obtain information on
the operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330.
The SEC also maintains a website site at
http://www.sec.gov
that contains reports, proxy statements, information statements
and other information filed electronically with the SEC. You may
also obtain information about us at our website at
http://www.conexant.com.
However, the information on our website does not constitute a
part of this prospectus.
INCORPORATION OF
CERTAIN DOCUMENTS BY REFERENCE
To avoid repeating information in this prospectus that we have
already filed with the SEC, we have incorporated by reference
the filings (File
No. 000-24923)
listed below. This information is considered a part of this
prospectus. These documents are as follows:
|
|
|
|
|
Our annual report on
Form 10-K
for our fiscal year ended October 2, 2009 (filed on
November 27, 2009), as amended by Amendment No. 1 on
Form 10-K/A
(filed on December 22, 2009);
|
|
|
|
Our current reports on
Form 8-K
filed on October 14, 2009, November 3, 2009,
November 13, 2009, November 18, 2009,
November 20, 2009, November 23, 2009, December 3,
2009, December 11, 2009 and December 24, 2009 (with
respect to Items 1.01, 5.03, 8.01 and Exhibits 3.2 and
99.2 of Item 9.01 only); and
|
|
|
|
The description of our common stock contained in Item 11 of
our Registration Statement on Form 10, as amended (File No.
000-24923),
including any amendment or report filed that updates such
description.
|
1
In addition, all documents that we file with the SEC pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Securities and
Exchange Act of 1934, as amended, after the date of the initial
registration statement of which this prospectus is a part and
prior to the effectiveness of the registration statement as well
as all such documents that we file with the SEC after the date
of this prospectus and before the termination of the offering of
our securities shall be deemed incorporated by reference into
this prospectus and to be a part of this prospectus from the
respective dates of filing such documents. Unless specifically
stated to the contrary, none of the information that we disclose
under Items 2.02 or 7.01 of any Current Report on
Form 8-K
that we may from time to time furnish to the SEC will be
incorporated by reference into, or otherwise included in, this
prospectus.
We will provide without charge to each person, including any
beneficial owner, to whom a copy of this prospectus has been
delivered, upon the written or oral request of such person, a
copy of any or all of the documents which have been incorporated
in this prospectus by reference. Requests for such copies should
be directed to our Secretary at Conexant Systems, Inc., 4000
MacArthur Boulevard, Newport Beach, California
92660-3095,
telephone number
(949) 483-4600.
Any statement contained in a document incorporated or deemed to
be incorporated by reference in this prospectus shall be deemed
modified, superseded or replaced for purposes of this prospectus
to the extent that a statement contained in this prospectus or
in any subsequently-filed document that also is or is deemed to
be incorporated by reference in this prospectus modifies,
supersedes or replaces such statement. Any statement so
modified, superseded or replaced shall not be deemed, except as
so modified, superseded or replaced, to constitute a part of
this prospectus.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus, any prospectus supplement, and the documents
incorporated herein and therein by reference contain
forward-looking statements within the meaning of the federal
securities laws. Any statements that do not relate to historical
or current facts or matters are forward-looking statements. You
can identify some of the forward-looking statements by the use
of forward-looking words, such as may,
will, could, project,
believe, anticipate, expect,
estimate, continue,
potential, plan, forecasts,
and the like, the negatives of such expressions, or the use of
future tense. Statements concerning current conditions may also
be forward-looking if they imply a continuation of current
conditions. Examples of forward-looking statements include, but
are not limited to, statements concerning:
|
|
|
|
|
our beliefs, subject to the qualifications expressed, regarding
the sufficiency of our existing sources of liquidity and cash to
fund our operations, research and development, anticipated
capital expenditures and our working capital needs for at least
the next 12 months and whether we will be able to
repatriate cash from our foreign operations on a timely and
cost-effective basis;
|
|
|
|
our belief that we will be able to sustain the recoverability of
our goodwill, intangible and tangible long-term assets;
|
|
|
|
expectations that we will have sufficient capital to repay our
indebtedness as it becomes due and to finance our ongoing
business and operations;
|
|
|
|
expectations that we will be able to continue to meet NASDAQ
listing requirements;
|
|
|
|
expectations regarding the market share of our products, growth
in the markets we serve and our market opportunities;
|
|
|
|
expectations regarding price and product competition;
|
|
|
|
continued demand and future growth in demand for our products in
the communications, PC and consumer markets we serve;
|
2
|
|
|
|
|
our plans and expectations regarding the transition of our
semiconductor products to smaller line width geometries;
|
|
|
|
our product development plans;
|
|
|
|
our expectation that our largest customers will continue to
account for a substantial portion of our revenue;
|
|
|
|
expectations regarding our contractual obligations and
commitments;
|
|
|
|
our expectation that we will be able to protect our products and
services with proprietary technology and intellectual property
protection;
|
|
|
|
our expectation that we will be able to meet our lease
obligations (and other financial commitments); and
|
|
|
|
our expectation that we will be able to continue to rely on
third party manufacturers to manufacture, assemble and test our
products to meet our customers demands.
|
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ
materially from those expressed in the forward-looking
statements. You are urged to carefully review the disclosures we
make concerning risks and other factors that may affect our
business and operating results, including, but not limited to,
those factors set forth in our most recent Annual Report on
Form 10-K
under the caption Risk Factors, and any of those
made in our other reports filed with the SEC. Please consider
our forward-looking statements in light of those risks as you
read this prospectus and any prospectus supplement. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this document.
Additional risks relating to our business, the industries in
which we operate or any securities we may offer and sell under
this prospectus may be described from time to time in our
filings with the SEC. We do not intend, and undertake no
obligation, to publish revised forward-looking statements to
reflect events or circumstances after the date of this document
or to reflect the occurrence of unanticipated events.
ABOUT CONEXANT
SYSTEMS, INC.
We design, develop and sell semiconductor system solutions,
comprised of semiconductor devices, software and reference
designs, for imaging, audio, embedded-modem, and video
applications. These solutions include a comprehensive portfolio
of imaging solutions for multifunction printers, fax platforms,
and connected frame market segments. Our audio
solutions include high-definition (HD) audio integrated
circuits, HD audio codecs, and
speakers-on-a-chip
solutions for personal computers (PCs), PC peripheral sound
systems, audio subsystems, speakers, notebook docking stations,
voice-over-IP speakerphones, intercom, door phone, and
audio-enabled surveillance applications. We also offer a full
suite of embedded-modem solutions for set-top boxes,
point-of-sale systems, home automation and security systems, and
desktop and notebook PCs. Additional products include decoders
and media bridges for video surveillance and security
applications, and system solutions for analog video-based
multimedia applications.
We market and sell our semiconductor products and system
solutions directly to leading original equipment manufacturers
(OEMs) of communication electronics products and indirectly
through electronic components distributors. We also sell our
products to third-party electronic manufacturing service
providers, who manufacture products incorporating our
semiconductor products for OEMs.
We were incorporated in Delaware in September 1996 and have been
operating in the communications semiconductor business,
including as part of the semiconductor systems business of
Rockwell International Corporation (now Rockwell Automation,
Inc.) since that time. We have been an independent public
company since January 1999, following our spin-off from
Rockwell. Since then, we have transformed our company from a
broad-based communications semiconductor supplier into a
3
fabless communications semiconductor supplier focused on
delivering the technology and products for imaging, audio,
embedded-modem, and video applications.
Our principal corporate office is located at 4000 MacArthur
Boulevard, Newport Beach, CA 92660, and our main telephone
number at that location is
(949) 483-4600.
We maintain a website at www.conexant.com. None of the
information contained on our website or on websites linked to
our website is part of this prospectus.
RISK
FACTORS
Investing in our securities involves a high degree of risk.
Before making an investment decision, you should carefully
consider any risk factors set forth in the applicable prospectus
supplement and the documents incorporated by reference into this
prospectus and the applicable prospectus supplement, as well as
other information we include or incorporate by reference into
this prospectus and in the applicable prospectus supplement.
USE OF
PROCEEDS
We will retain broad discretion over the use of the net proceeds
to us from any sale of our securities under this prospectus. We
intend to use the net proceeds from the sale of the securities
for general corporate purposes, including, but not limited, to
repaying, redeeming or repurchasing existing debt, and for
working capital, capital expenditures and acquisitions. Pending
application of the net proceeds, we may initially invest the net
proceeds in short-term investment grade securities.
RATIO OF EARNINGS
TO FIXED CHARGES
Our ratio of earnings to fixed charges, for the periods
indicated, are set forth below:
|
|
|
|
|
|
|
|
|
Fiscal Year(1)
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
See footnote(2)
|
|
1.17
|
|
See footnote(2)
|
|
1.57
|
|
0.35
|
|
|
|
(1) |
|
Our fiscal year ends on the Friday nearest to September 30 of
each year. |
|
(2) |
|
For purposes of calculating this ratio, earnings consist of
income (loss) from continuing operations before (i) income
taxes and (ii) income (loss) from equity method
investments, plus the addition of (i) distributed income of
equity investees and (ii) fixed charges. Fixed charges
consist of interest expense, including amortization of debt
issuance costs, and the portion of rent expense which we believe
is representative of the interest component of rental expense.
For fiscal years 2009 and 2007, earnings were insufficient to
cover fixed charges by approximately $22.4 million and
$217.8 million, respectively. |
4
DESCRIPTION OF
CAPITAL STOCK
General
This prospectus describes the general terms of our common and
preferred stock. For a more detailed description of these
securities, you should read the applicable provisions of
Delaware law and our certificate of incorporation and bylaws.
When we offer to sell a particular series of these securities,
we will describe the specific terms of the series in a
supplement to this prospectus. Accordingly, for a description of
the terms of any series of these securities, you must refer to
both the prospectus supplement relating to that series and the
description of the securities described in this prospectus. To
the extent the information contained in the prospectus
supplement differs from this summary description, you should
rely on the information in the prospectus supplement.
Our authorized capital stock consists of:
|
|
|
|
|
100,000,000 shares of common stock, par value $0.01 per
share; and
|
|
|
|
25,000,000 shares of preferred stock, no par value.
|
As of December 22, 2009, there were 65,029,932 shares
of common stock outstanding and no shares of preferred stock
outstanding.
Certain of the provisions described under this section entitled
Description of Capital Stock could have the effect
of discouraging transactions that might lead to a change of
control of Conexant.
Our restated certificate of incorporation and by-laws:
|
|
|
|
|
establish a classified board of directors, whereby our directors
are elected for staggered terms in office so that only one-third
of our directors stand for election in any one year;
|
|
|
|
require stockholders to provide advance notice of any
stockholder nominations for directors or any proposal of new
business to be considered at any meeting of stockholders;
|
|
|
|
require a supermajority vote to remove a director or to amend or
repeal certain provisions of our restated certificate of
incorporation or by-laws;
|
|
|
|
preclude stockholders from acting by written consent without a
meeting of stockholders; and
|
|
|
|
preclude stockholders from calling a special meeting of
stockholders.
|
Common
Stock
Holders of common stock are entitled to such dividends as may be
declared by our board of directors out of funds legally
available therefor. Dividends may not be paid on common stock
unless all accrued dividends on preferred stock, if any, have
been paid or set aside. In the event of our liquidation,
dissolution or winding up, the holders of common stock will be
entitled to share pro rata in the assets remaining after payment
to creditors and after payment of the liquidation preference
plus any unpaid dividends to holders of any outstanding
preferred stock.
Each holder of shares of common stock will be entitled to one
vote for each such share outstanding in the holders name.
No holder of common stock will be entitled to cumulate votes in
voting for directors. Our restated certificate of incorporation
provides that, unless otherwise determined by our board of
directors, no holder of shares of common stock will have any
right to purchase or subscribe for any stock of any class that
we may issue or sell.
Preferred
Stock
Our restated certificate of incorporation permits us to issue up
to 25,000,000 shares of our preferred stock in one or more
series and with rights and preferences that may be fixed or
designated by our board of directors without any further action
by our stockholders. The powers, preferences,
5
rights and qualifications, limitations and restrictions of the
preferred stock of any series will be fixed by the certificate
of designation relating to such series, which will specify the
terms of the preferred stock, including:
|
|
|
|
|
the maximum number of shares in the series and the distinctive
designation;
|
|
|
|
the terms on which dividends, if any, will be paid;
|
|
|
|
the terms on which the shares may be redeemed, if at all;
|
|
|
|
the terms of any retirement or sinking fund for the purchase or
redemption of the shares of the series;
|
|
|
|
the liquidation preference, if any;
|
|
|
|
the terms and conditions, if any, on which the shares of the
series shall be convertible into, or exchangeable for, shares of
any other class or classes of capital stock;
|
|
|
|
the restrictions on the issuance of shares of the same series or
any other class or series; and
|
|
|
|
the voting rights, if any, of the shares of the series.
|
Although our board of directors has no intention at the present
time of doing so, it could issue a series of preferred stock
that could, depending on the terms of such series, impede the
completion of a merger, tender offer or other takeover attempt.
Anti-Takeover
Provisions
We are governed by the Delaware General Corporation Law, or
DGCL. Our certificate of incorporation and bylaws contain
provisions that could make more difficult the acquisition of the
company by means of a tender offer, a proxy contest or otherwise.
Classified
Board
Our certificate of incorporation provides that our directors,
other than those who may be elected by the holders of preferred
stock or any other series or class of stock, shall be divided
into three classes of directors, as nearly equal in number as
possible, with overlapping three-year terms. One class of
directors is to be elected each year with a term extending to
the third succeeding annual meeting after election. The
classification of the board has the effect of requiring at least
two annual stockholders meetings, instead of one, to replace a
majority of the members of the board of directors.
Supermajority
Vote
Our certificate of incorporation provides that the affirmative
vote of at least 80% in voting power of the outstanding shares
of our capital stock entitled to vote generally in the election
of directors, voting together as a single class is required:
(i) to remove any director from office at any time, which
removal may only be for cause, (ii) in order for our
stockholders to amend, alter or repeal our bylaws and
(iii) to amend or repeal certain provisions of our
certificate of incorporation, including those related to
limiting liabilities of directors and removing directors.
Our restated certificate of incorporation also contains fair
price provisions pursuant to which a Business Combination (as
defined in our restated certificate of incorporation) between us
or one of our subsidiaries and an Interested Shareowner (as
defined in our restated certificate of incorporation) requires
approval by the affirmative vote of the holders of not less than
80 percent of the voting power of all of our outstanding
capital stock entitled to vote generally in the election of
directors, voting together as a single class, unless the
Business Combination is approved by at least two-thirds of the
Continuing Directors (as defined in our restated certificate of
incorporation) or certain fair price criteria and procedural
requirements specified in the fair price provision are met. If
either the requisite approval of our board of directors or the
fair price criteria and procedural requirements were met, the
6
Business Combination would be subject to the voting requirements
otherwise applicable under the DGCL, which for most types of
Business Combinations currently would be the affirmative vote of
the holders of a majority of all of our outstanding shares of
stock entitled to vote thereon. Any amendment or repeal of the
fair price provisions, or the adoption of provisions
inconsistent therewith, must be approved by the affirmative vote
of the holders of not less than 80 percent of the voting
power of all of our outstanding capital stock entitled to vote
generally in the election of directors, voting together as a
single class, unless such amendment, repeal or adoption were
approved by at least two-thirds of the Continuing Directors, in
which case the provisions of the DGCL would require the
affirmative vote of the holders of a majority of the outstanding
shares of our capital stock entitled to vote thereon.
Advance Notice
Procedures
Our bylaws establish an advance notice procedure for
stockholders to make nominations of candidates for election as
directors at an annual or special meeting of the stockholders or
bring other business before an annual meeting of the
stockholders. This notice procedure provides that, in order to
nominate candidates for election as directors or raise other
matters at an annual meeting, the nominations must be made or
the matters must be raised in the companys notice of
meeting, or by or at the direction of our board of directors, or
by a stockholder who (i) is a stockholder of record at the
time of giving notice as required by the bylaws, (ii) is
entitled to vote at the meeting, and (iii) complies with
the notice provisions of the bylaws. If our chairman or other
officer presiding at a meeting determines that a person was not
nominated or other business was not brought before the annual
meeting in accordance with the notice procedure, that person
will not be eligible for election as a director or that business
will not be conducted at the meeting.
Special Meetings
of Stockholders
Under our bylaws, stockholders may not call a special meeting of
the stockholders and the only business to be conducted at a
special meeting of the stockholders will be the business brought
before the meeting pursuant to the companys notice of
meeting.
Authorized but
Unissued Shares
Our authorized but unissued shares of common stock are available
for future issuance without stockholder approval, subject to any
limitations imposed by the listing standards of the NASDAQ
Global Select Market. We may use these additional shares for a
variety of corporate purposes, including future public offerings
to raise additional capital, corporate acquisitions and employee
benefit plans. Our board of directors also has the ability to
issue shares of our authorized but unissued preferred stock in
one or more series without further stockholder approval. The
existence of authorized but unissued shares of common and
preferred stock could render more difficult or discourage an
attempt to obtain control of us by means of a proxy contest,
tender offer, merger or otherwise.
Action by Written
Consent
Our bylaws do not permit stockholder action by written consent.
The overall effect of the foregoing provisions may be to deter a
future tender offer. Stockholders might view such an offer to be
in their best interest should the offer include a substantial
premium over the market price of our common stock at that time.
In addition, these provisions may have the effect of assisting
our management to retain its position and place it in a better
position to resist changes that the stockholders may want to
make if dissatisfied with the conduct of our business.
The Delaware
General Corporation Law
We are subject to Section 203 of the DGCL, which regulates
corporate acquisitions. In general, Section 203 prohibits a
publicly-held Delaware corporation from engaging in a business
combination
7
with an interested stockholder for a period of three years
following the date the person became an interested stockholder,
unless:
|
|
|
|
|
the board of directors approved the transaction in which the
stockholder became an interested stockholder prior to the date
the interested stockholder attained such status;
|
|
|
|
upon consummation of the transaction that resulted in the
stockholder becoming an interested stockholder, the interested
stockholders owned at least 85% of the voting stock of the
corporation outstanding at the time the transaction commenced,
excluding shares owned by persons who are directors and also
officers and employee stock plans in which employee participants
do not have the right to determine confidentially whether shares
held subject to the plan will be tendered in a tender or
exchange offer; or
|
|
|
|
the business combination is approved by a majority of the board
of directors and by the affirmative vote of at least two-thirds
of the outstanding voting stock that is not owned by the
interested stockholder.
|
Transfer Agent
and Registrar
The Transfer Agent and Registrar for our common stock is BNY
Mellon Shareowner Services.
Listing
Our shares of common stock are quoted on the NASDAQ Global
Select Market under the symbol CNXT.
DESCRIPTION OF
DEBT SECURITIES
The following description discusses the general terms and
provisions of the debt securities that we may offer by this
prospectus. The debt securities will be issued as
(i) senior debt securities, which will rank equally with
all of our other unsubordinated debt, or (ii) subordinated
debt securities, which will rank equally with all of our other
subordinated debt.
We will issue any senior notes under the senior indenture which
we will enter into with the trustee named in the senior
indenture. We will issue any subordinated notes under the
subordinated indenture which we will enter into with the trustee
named in the subordinated indenture. We have filed forms of
these documents as exhibits to the registration statement.
Unless otherwise indicated in the applicable prospectus
supplement, The Bank of New York Mellon Trust Company, N.A
will be the trustee under both the senior and subordinated
indentures. The Bank of New York Mellon Trust Company, N.A.
(formerly known as The Bank of New York Trust Company,
N.A.), as successor to J.P. Morgan Trust Company,
National Association, also acts as the trustee under the
indenture, dated March 7, 2006, governing our 4%
convertible subordinated notes.
Except as we may otherwise indicate, the terms of the senior
indenture and the subordinated indenture are identical. We use
the term indentures to refer to both the senior
indenture and the subordinated indenture. We use the term
indenture trustee to refer to either the senior
trustee or the subordinated trustee, as applicable. The
indentures are subject to and governed by the
Trust Indenture Act of 1939, or the Trust Indenture
Act, and may be supplemented or amended from time to time
following their execution. The indentures give us broad
authority to set the particular terms of each series of debt
securities, including the right to modify certain of the terms
contained in the indentures. The particular terms of a series of
debt securities and the extent, if any, to which the particular
terms of the issue modify the terms of the indentures will be
described in the prospectus supplement relating to the debt
securities.
For more information about the debt securities offered by us,
please refer to the indentures, which contain the full legal
text of the matters described in this section. Because this
section is a summary, it does not describe every aspect of the
debt securities or the indentures. This summary is
8
subject to and qualified in its entirety by reference to all the
provisions of the indentures, including definitions of terms
used in the indentures. This summary also is subject to and
qualified by reference to the description of the particular
terms of the debt securities in the applicable prospectus
supplement.
General
The indentures do not limit the aggregate principal amount of
debt securities that may be issued thereunder. The debt
securities may be issued from time to time in one or more
series. We will describe in the applicable prospectus supplement
the terms relating to a series of debt securities, including:
|
|
|
|
|
the title;
|
|
|
|
the principal amount being offered, and, if a series, the total
amount authorized and the total amount outstanding;
|
|
|
|
any limit on the amount that may be issued;
|
|
|
|
whether or not we will issue the series of debt securities in
global form and, if so, the terms and who the depositary will be;
|
|
|
|
the maturity date(s);
|
|
|
|
the principal amount due at maturity, and whether the debt
securities will be issued with any original issue discount;
|
|
|
|
whether and under what circumstances, if any, we will pay
additional amounts on any debt securities held by a person who
is not a U.S. person for tax purposes, and whether we can
redeem the debt securities if we have to pay such additional
amounts;
|
|
|
|
the interest rate(s), which may be fixed or variable, or the
method for determining the rate, the date interest will begin to
accrue, the dates interest will be payable and the regular
record dates for interest payment dates or the method for
determining such dates;
|
|
|
|
whether or not the debt securities will be secured or unsecured,
and the terms of any secured debt;
|
|
|
|
the terms of the subordination of any series of subordinated
debt;
|
|
|
|
the place where payments will be payable;
|
|
|
|
restrictions on transfer, sale or other assignment, if any;
|
|
|
|
our right, if any, to defer payment of interest and the maximum
length of any such deferral period;
|
|
|
|
the date, if any, after which, the conditions upon which, and
the price at which we may, at our option, redeem the series of
debt securities pursuant to any optional or provisional
redemption provisions, and any other applicable terms of those
redemption provisions;
|
|
|
|
provisions for a sinking fund, purchase or other analogous fund,
if any;
|
|
|
|
the date, if any, on which, and the price at which we are
obligated, pursuant to any mandatory sinking fund or analogous
fund provisions or otherwise, to redeem, or at the holders
option to purchase, the series of debt securities;
|
|
|
|
whether the indenture will restrict our ability
and/or the
ability of our subsidiaries to:
|
|
|
|
|
|
incur additional indebtedness;
|
|
|
|
issue additional securities;
|
9
|
|
|
|
|
create liens;
|
|
|
|
pay dividends or make distributions in respect of our capital
stock and the capital stock of our subsidiaries;
|
|
|
|
redeem capital stock;
|
|
|
|
place restrictions on our subsidiaries ability to pay
dividends, make distributions or transfer assets;
|
|
|
|
make investments or other restricted payments;
|
|
|
|
sell or otherwise dispose of assets;
|
|
|
|
enter into sale-leaseback transactions;
|
|
|
|
engage in transactions with stockholders and affiliates;
|
|
|
|
issue or sell stock of or sell assets of our subsidiaries; or
|
|
|
|
effect a consolidation or merger;
|
|
|
|
|
|
whether the indenture will require us to maintain any interest
coverage, fixed charge, cash flow-based, asset-based or other
financial ratios;
|
|
|
|
a discussion of any material or special U.S. federal income
tax considerations applicable to the debt securities;
|
|
|
|
information describing any book-entry features;
|
|
|
|
the procedures for any auction and remarketing, if any;
|
|
|
|
the denominations in which we will issue the series of debt
securities, if other than denominations of $1,000 and any
integral multiple thereof;
|
|
|
|
if other than U.S. dollars, the currency in which the
series of debt securities will be denominated; and
|
|
|
|
any other terms of the series of debt securities (which shall
not be inconsistent with the provisions of the indentures,
except as permitted by a supplemental indenture, but which may
modify or delete any provisions of the indentures insofar as it
applies to such series), including any terms which may be
required by or advisable under the laws of the U.S. or
regulations thereunder or advisable (as determined by us) in
connection with the marketing of the debt securities of the
series.
|
One or more series of the debt securities may be issued as
discounted debt securities (bearing no interest or interest at a
rate which at the time of issuance is below market rates) to be
sold at a substantial discount below their stated principal
amount. Material U.S. federal income tax consequences and
other special considerations applicable to any such discounted
debt securities will be described in the prospectus supplement
relating thereto.
Conversion or
Exchange Rights
We will set forth in the prospectus supplement the terms on
which a series of debt securities may be convertible into or
exchangeable for our common stock or other securities, including
the conversion or exchange rate, as applicable, or how it will
be calculated, and the applicable conversion or exchange period.
We will include provisions as to whether conversion or exchange
is mandatory, at the option of the holder or at our option. We
may include provisions pursuant to which the number of our
securities that the holders of the series of debt securities
receive upon conversion or exchange would, under the
circumstances described in those provisions, be subject to
adjustment, or pursuant to which those holders would, under
those circumstances, receive other property upon conversion or
exchange, for example in the event of our merger or
consolidation with another entity.
10
Consolidation,
Merger or Sale
The indentures in the forms initially filed as exhibits to the
registration statement of which this prospectus is a part do not
contain any covenant that restricts our ability to merge or
consolidate, or sell, convey, transfer or otherwise dispose of
all or substantially all of our assets. However, any successor
of ours or acquiror of such assets must assume all of our
obligations under the indentures and the debt securities.
If the debt securities are convertible into our other
securities, the person with whom we consolidate or merge or to
whom we sell all of our property must make provisions for the
conversion of the debt securities into securities which the
holders of the debt securities would have received if they had
converted the debt securities before the consolidation, merger
or sale.
Limited
Restrictions
Unless we otherwise state in the prospectus supplement, the
indentures do not limit our ability to incur debt and do not
give holders of debt securities protection in the event of a
sudden and significant decline in our credit quality or a
takeover, recapitalization or highly leveraged or similar
transaction involving us. Accordingly, we could in the future
enter into transactions that could increase the amount of
indebtedness outstanding at that time or otherwise affect our
capital structure or credit rating.
Events of
Default
The following are events of default under the indentures with
respect to any series of debt securities that we may issue:
|
|
|
|
|
if we fail to pay interest when due and payable and our failure
continues for 30 days and the time for payment has not been
extended or deferred;
|
|
|
|
if we fail to pay the principal, or premium, if any, when due
and payable and the time for payment has not been extended or
delayed;
|
|
|
|
if we fail to observe or perform any other covenant contained in
the debt securities or the indentures, other than a covenant
solely for the benefit of another series of debt securities, and
our failure continues for 90 days after we receive notice
from the indenture trustee or holders of at least 25% in
aggregate principal amount of the outstanding debt securities of
the applicable series; and
|
|
|
|
if specified events of bankruptcy, insolvency or reorganization
occur.
|
We will periodically file statements with the indenture trustee
regarding our compliance with the covenants in the indentures.
Remedies
Acceleration
If an event of default with respect to debt securities of any
series occurs and is continuing, other than an event of default
specified in the last bullet point above, the indenture trustee
or the holders of at least 25% in aggregate principal amount of
the outstanding debt securities of that series, by notice to us
in writing, and to the indenture trustee if notice is given by
such holders, may declare the unpaid principal of, premium, if
any, and accrued interest, if any, due and payable immediately.
If an event of default specified in the last bullet point above
occurs with respect to us, the principal amount of and accrued
interest, if any, of each series of debt securities then
outstanding shall be due and payable without any notice or other
action on the part of the indenture trustee or any holder.
Subject to the terms of the indentures, if an event of default
under an indenture shall occur and be continuing, the indenture
trustee will be under no obligation to exercise any of its
rights or powers
11
under such indenture at the request or direction of any of the
holders of the applicable series of debt securities, unless such
holders have offered the indenture trustee reasonable indemnity.
Rescission of
Acceleration
After the declaration of acceleration has been made and before
the indenture trustee has obtained a judgment or decree for
payment of the moneys due on any series of debt securities, the
registered holders of not less than a majority in aggregate
principal amount of the outstanding debt securities of that
series may rescind and annul the declaration and its
consequences by written notice to us and the indenture trustee,
if:
|
|
|
|
|
we pay or deposit with the indenture trustee a sum sufficient to
pay:
|
|
|
|
all matured interest, other than interest which has become due
by declaration of acceleration;
|
|
|
|
the principal of and any premium which have become due other
than by the declaration of acceleration and interest on these
amounts;
|
|
|
|
interest on overdue interest, other than interest which has
become due by declaration of acceleration, to the extent
lawful; and
|
|
|
|
all amounts due to the indenture trustee under the
indenture; and
|
|
|
|
all events of default with respect to the affected series, other
than the nonpayment of the principal and interest (and premium,
if any) which has become due solely by the declaration of
acceleration, have been remedied or waived as provided in the
indenture.
|
For more information as to waiver of defaults, see Waiver
of Default below.
Control by
Registered Holders; Limitations
The holders of a majority in principal amount of the outstanding
debt securities of any series will have the right to direct the
time, method and place of conducting any proceeding for any
remedy available to the indenture trustee, or exercising any
trust or power conferred on the indenture trustee, with respect
to the debt securities of that series, provided that:
|
|
|
|
|
the direction so given by the holder is not in conflict with any
law or the applicable indenture; and
|
|
|
|
subject to its duties under the Trust Indenture Act, the
indenture trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the
holders not involved in the proceeding.
|
A holder of the debt securities of any series will only have the
right to institute a proceeding under the indentures or to
appoint a receiver or trustee, or to seek other remedies if:
|
|
|
|
|
the holder has given written notice to the indenture trustee of
a continuing event of default with respect to that series;
|
|
|
|
the holders of at least 25% in aggregate principal amount of the
outstanding debt securities of that series have made written
request, and such holders have offered reasonable indemnity to
the indenture trustee, to institute the proceeding as
trustee; and
|
|
|
|
the indenture trustee does not institute the proceeding, and
does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that
series other conflicting directions, within 90 days after
the notice, request and offer.
|
These limitations do not apply to a suit instituted by a holder
of debt securities if we default in the payment of the
principal, premium, if any, or interest on, the debt securities.
12
Notice of
Default
The indenture trustee is required to give the registered holders
of the debt securities notice of any default under the
indentures known by the indenture trustee to the extent required
by the Trust Indenture Act, unless the default has been
cured or waived. The Trust Indenture Act currently permits
the indenture trustee to withhold notices of default (except for
certain payment defaults) if the indenture trustee in good faith
determines the withholding of the notice to be in the interests
of the registered holders.
Waiver of
Default
The holders of a majority in principal amount of the outstanding
debt securities of an affected series may waive any default or
event of default with respect to the series and its
consequences, except defaults or events of default regarding
payment of principal, premium, if any, or interest, unless we
have cured the default or event of default in accordance with
the applicable indenture.
Modification of
Indentures; Waiver
We and the indenture trustee may change an indenture without the
consent of any holders with respect to specific matters,
including:
|
|
|
|
|
to fix any ambiguity, defect or inconsistency in the indenture;
|
|
|
|
to comply with the provisions described above under
Consolidation, Merger or Sale, including
to evidence the succession of another person to us and the
assumption by any such successor of our obligations under the
indenture and in the debt securities;
|
|
|
|
to comply with any requirements of the SEC in connection with
the qualification of any indenture under the
Trust Indenture Act;
|
|
|
|
to evidence and provide for the acceptance of appointment of a
successor trustee under the indenture;
|
|
|
|
to provide for uncertificated debt securities;
|
|
|
|
to add to, delete from, or revise the conditions, limitations
and restrictions on the authorized amount, terms or purposes of
issuance, authorization and delivery of debt securities of any
unissued series;
|
|
|
|
to add any additional events of default;
|
|
|
|
to provide for the issuance of and establish the form and terms
and conditions of any series of debt securities as provided in
an indenture, to establish the form of any certifications
required to be furnished pursuant to an indenture or any series
of debt securities, or to add to the rights of the holders of
any series of debt securities;
|
|
|
|
to add to our covenants such new covenants, restrictions,
conditions or provisions for the protection of the holders, to
make the occurrence, or the occurrence and the continuance, of a
default in any such additional covenants, restrictions,
conditions or provisions an event of default, or to surrender
any of our rights or powers under the indenture;
|
|
|
|
to provide security for the debt securities of any
series; or
|
|
|
|
to make any other provisions with respect to matters or
questions arising under the indenture, provided that such action
shall not adversely affect the interests of the holders of any
series of debt securities or any related coupons in any material
respect.
|
In addition, under the indentures, the rights of holders of a
series of debt securities may be changed by us and the indenture
trustee with the written consent of the holders of at least a
majority in aggregate principal amount of the outstanding debt
securities of each series that is affected.
13
However, we and the indenture trustee may only make the
following changes with the consent of each holder of any
outstanding debt securities affected:
|
|
|
|
|
reduce the percentage of debt securities, the holders of which
are required to consent to any supplemental indenture;
|
|
|
|
reduce the rate of interest or extend the time for payment of
interest on such debt securities or reduce any premium payable
upon the redemption thereof;
|
|
|
|
reduce the principal amount of such debt securities;
|
|
|
|
extend the fixed maturity of such debt securities; or
|
|
|
|
reduce the redemption or repurchase price of such debt
securities or change the time at which such debt securities may
or must be redeemed or repurchased.
|
Satisfaction and
Discharge
An indenture will cease to be of further effect with respect to
any series of debt securities, and we will be deemed to have
satisfied and discharged all of our obligations under such
indenture, except as noted below, when, among other conditions:
|
|
|
|
|
all outstanding debt securities of such series have become due
or will become due within one year at their stated maturity or
on a redemption date or have been delivered to the indenture
trustee for cancellation; and
|
|
|
|
we deposit with the indenture trustee, in trust, funds that are
sufficient to pay and discharge all remaining indebtedness on
the outstanding debt securities of such series not delivered to
the indenture trustee for cancellation.
|
We will remain obligated to pay all other amounts due under such
indenture and to perform certain ministerial tasks to be
described in the indenture.
Legal Defeasance
and Covenant Defeasance
The indentures provide that we may elect to be:
|
|
|
|
|
discharged from (and be deemed to have satisfied) our
obligations (except for certain obligations to register the
transfer or exchange of debt securities, to replace stolen, lost
or mutilated debt securities, to maintain paying agencies and
hold monies for payment in trust and, if so specified with
respect to the debt securities of a certain series, to pay the
principal of (and premium, if any) and interest, if any, on such
specified debt securities), with respect to any series of debt
securities, which we refer to as legal
defeasance; and
|
|
|
|
released from our obligations under specified covenants with
respect to any series of debt securities, which we refer to as
covenant defeasance.
|
Among other conditions we must satisfy in order to effect a
legal defeasance or a covenant defeasance is the deposit with
the indenture trustee, in trust, of cash
and/or
Governmental Obligations (as defined in the indentures) which
through the payment of interest and principal thereof in
accordance with their terms will provide funds in an amount
sufficient to pay any installment of principal (and premium, if
any (and interest, if any)), on and any mandatory sinking fund
payments in respect of such debt securities on the stated
maturity of such payments in accordance with the terms of the
indentures and such debt securities.
Such a trust may be established only if, among other things, we
have delivered to the indenture trustee an opinion of counsel
(who may be our counsel) to the effect that,
|
|
|
|
|
in the case of a legal defeasance, (x) we have received
from the Internal Revenue Service a private letter ruling or
there has been published by the Internal Revenue Service a
revenue
|
14
|
|
|
|
|
ruling pertaining to a comparable form of transaction, or
(y) since the date of the execution of the applicable
indenture there has been a change in the applicable federal
income tax law, in either case to the effect that, and based
thereon such opinion of counsel shall confirm that, the holders
of the outstanding debt securities of such series will not
recognize income, gain or loss for federal income tax purposes
as a result of such legal defeasance and will be subject to
federal income tax on the same amounts, in the same manner and
at the same times as would have been the case if such legal
defeasance had not occurred; and
|
|
|
|
|
|
in the case of a covenant defeasance, the holders of the
outstanding debt securities of such series will not recognize
income, gain or loss for federal income tax purposes as a result
of such covenant defeasance and will be subject to federal
income tax on the same amounts, in the same manner and at the
same times as would have been the case if such covenant
defeasance had not occurred.
|
Redemption
We will set forth any terms for the redemption of debt
securities in a prospectus supplement. Unless we indicate
differently in a prospectus supplement, all or any portion of
the debt securities may be redeemed at our option at any time
and from time to time. Unless otherwise specified in a
resolution of our board of directors and in a supplemental
indenture (including any pricing supplement) or in one or more
certificates of one or more of our officers with respect to any
debt securities, the debt securities will be redeemable upon
notice by mail between 30 and 90 days prior to the
redemption date. If less than all of the debt securities of any
series or any tranche of a series are to be redeemed, the
indenture trustee will select the debt securities to be redeemed
by lot or in such manner as it deems appropriate and fair.
Debt securities will cease to bear interest on the redemption
date. We will pay the redemption price and any accrued interest
once you surrender the debt security for redemption. If only
part of a debt security is redeemed, the indenture trustee will
deliver to you a new debt security of the same series for the
unredeemed portion without charge.
Form,
Authentication, Delivery, Exchange and Transfer
Form
We will issue the debt securities of each series only in fully
registered form without coupons and, unless we otherwise specify
in the applicable prospectus supplement, in denominations of
$1,000 and any integral multiple thereof. We may issue debt
securities of a series in temporary or permanent global form and
as book-entry securities that will be deposited with, or on
behalf of, The Depository Trust Company or another
depositary named by us and identified in a prospectus supplement
with respect to that series.
Authentication
and Delivery
The debt securities will be signed on our behalf by one of our
officers and, to the extent necessary, under our corporate seal.
A debt security will not be valid until authenticated manually
by the indenture trustee, or by an authenticating agent duly
appointed by the indenture trustee. Such signature will be
conclusive evidence that the debt security so authenticated has
been duly authenticated and delivered under the applicable
indenture and that the holder is entitled to the benefits of the
applicable indenture. At any time after the execution and
delivery of the applicable indenture, we may deliver executed
debt securities of any series to the indenture trustee for
authentication, together with a written order by us for the
authentication and delivery of such debt securities, and the
indenture trustee in accordance with such order shall
authenticate and deliver such debt securities.
15
The indenture trustee will not be required to authenticate any
debt securities if the issuance of such debt securities pursuant
to the applicable indenture will affect the indenture
trustees own rights, duties or immunities under the debt
securities and the applicable indenture or otherwise in a manner
that is not reasonably acceptable to the indenture trustee.
Debt securities issued in global form will be delivered by the
indenture trustee to the depositary or pursuant to the
depositarys instructions.
Exchange and
Transfer
At the option of the holder, subject to the terms of the
indentures and the limitations applicable to global securities
described in the applicable prospectus supplement, the holder of
the debt securities of any series can exchange the debt
securities for other debt securities of the same series, in any
authorized denomination and of like tenor and aggregate
principal amount.
Subject to the terms of the indentures and the limitations
applicable to global securities set forth in the applicable
prospectus supplement, holders of the debt securities may
present the debt securities for exchange or for registration of
transfer, duly endorsed or with the form of transfer endorsed
thereon duly executed if so required by us or the security
registrar, at the office of the security registrar. Unless
otherwise provided in the debt securities that the holder
presents for transfer or exchange, we will make no service
charge for any registration of transfer or exchange, but we or
the indenture trustee may require payment of any taxes or other
governmental charges.
We will name in the applicable prospectus supplement the
security registrar that we initially designate for any debt
securities. We may at any time designate additional security
registrars or rescind the designation of any security registrar
or approve a change in the office through which any security
registrar acts.
If we elect to redeem the debt securities of any series, we will
not be required to:
|
|
|
|
|
issue, register the transfer of, or exchange any debt securities
of any series being redeemed in part during a period beginning
at the opening of business 15 days before the day of
mailing of a notice of redemption of any debt securities that
may be selected for redemption and ending at the close of
business on the day of the mailing; or
|
|
|
|
register the transfer of or exchange any debt securities so
selected for redemption, in whole or in part, except the
unredeemed portion of any debt securities we are redeeming in
part.
|
Information
Concerning the Indenture Trustee
The indenture trustee, other than during the occurrence and
continuance of an event of default under an indenture,
undertakes to perform only those duties as are specifically set
forth in the applicable indenture. Upon an event of default
under an indenture, the indenture trustee must use the same
degree of care as a prudent person would exercise or use in the
conduct of his or her own affairs. The indenture trustee is
under no obligation to exercise any of the powers given it by
the indentures at the request of any holder of debt securities
unless it is offered reasonable security and indemnity against
the costs, expenses and liabilities that it might incur.
Upon any request by us to the indenture trustee to take any
action under an indenture, we will furnish to the indenture
trustee (i) an officers certificate stating that all
conditions precedent provided for in the applicable indenture
relating to the proposed action have been complied with and
(ii) an opinion of counsel stating that in the opinion of
such counsel all such conditions precedent have been complied
with. In the case of any request as to which the furnishing of
certificates or opinions by us is specifically required by the
applicable provision of an indenture, no additional certificates
or opinions need be furnished by us.
16
Resignation and
Removal of Trustee
The indenture trustee may resign at any time by giving written
notice to us and the registered holders of debt securities of
the applicable series. The indenture trustee may also be removed
by act of the registered holders of a majority in principal
amount of the then outstanding debt securities of any series,
and in certain circumstances may be removed by us.
No resignation or removal of the indenture trustee and no
appointment of a successor indenture trustee will become
effective until the acceptance of appointment by a successor
indenture trustee in accordance with the requirements of the
indentures.
Payment and
Paying Agents
Unless we otherwise indicate in the applicable prospectus
supplement, we will make payment of the interest on any debt
securities on any interest payment date to the person in whose
name the debt securities, or one or more predecessor securities,
are registered at the close of business on the regular record
date for the interest.
We will pay principal of, and any premium and interest on, the
debt securities of a particular series at the office of the
paying agents designated by us, except that, unless we otherwise
indicate in the applicable prospectus supplement, we may make
payments of principal or interest by check which we will mail to
the holder or by wire transfer to certain holders. Unless we
otherwise indicate in a prospectus supplement, we will designate
an office or agency of the indenture trustee in the City of New
York as our paying agent for payments with respect to debt
securities of each series. We will name in the applicable
prospectus supplement any other paying agents that we initially
designate for the debt securities of a particular series. We
will maintain a paying agent in each place of payment for the
debt securities of a particular series.
Any cash or Governmental Obligations we pay to a paying agent or
the indenture trustee for the payment of the principal of or any
premium or interest on any debt securities which remains
unclaimed at the end of two years after such principal, premium
or interest has become due and payable will be repaid to us, and
the holder of the debt security thereafter may look only to us
for payment thereof.
Governing
Law
The indentures and the debt securities will be governed by and
construed in accordance with the laws of the State of New York,
except to the extent that the Trust Indenture Act is
applicable.
Subordination of
Subordinated Debt Securities
The subordinated debt securities will be subordinate and junior
in priority of payment to certain of our other indebtedness to
the extent described in a prospectus supplement.
17
DESCRIPTION OF
WARRANTS
We may issue warrants to purchase debt securities (debt
warrants), preferred stock (preferred stock
warrants) or common stock (common stock
warrants, and collectively with the debt warrants and the
preferred stock warrants, warrants). We may issue
warrants independently or together with any other securities we
offer pursuant to a prospectus supplement and the warrants may
be attached or separate from the securities. We will issue each
series of warrants under a separate warrant agreement that we
will enter into with a bank or trust company, as warrant agent.
Debt
Warrants
We will describe in the applicable prospectus supplement the
terms of the debt warrants being offered, the warrant agreement
relating to the debt warrants and the debt warrant certificates
representing the debt warrants, including the following:
|
|
|
|
|
the title of the debt warrants;
|
|
|
|
the aggregate number of the debt warrants;
|
|
|
|
the price or prices at which the debt warrants will be issued;
|
|
|
|
the designation, aggregate principal amount and terms of the
debt securities purchasable upon exercise of the debt warrants,
and the procedures and conditions relating to the exercise of
the debt warrants;
|
|
|
|
the designation and terms of any related debt securities with
which the debt warrants are issued, and the number of the debt
warrants issued with each security;
|
|
|
|
the date, if any, on and after which the debt warrants and the
related debt securities will be separately transferable;
|
|
|
|
the principal amount of debt securities purchasable upon
exercise of each debt warrant, and the price at which the
principal amount of the debt securities may be purchased upon
exercise;
|
|
|
|
the date on which the right to exercise the debt warrants will
commence, and the date on which the right will expire;
|
|
|
|
the maximum or minimum number of the debt warrants which may be
exercised at any time;
|
|
|
|
a discussion of the material U.S. federal income tax
considerations applicable to the exercise of the debt
warrants; and
|
|
|
|
any other terms of the debt warrants and terms, procedures and
limitations relating to the exercise of the debt warrants.
|
Holders may exchange debt warrant certificates for new debt
warrant certificates of different denominations, and may
exercise debt warrants at the corporate trust office of the
warrant agent or any other office indicated in the applicable
prospectus supplement. Prior to the exercise of their debt
warrants, holders of debt warrants will not have any of the
rights of holders of the securities purchasable upon the
exercise and will not be entitled to payments principal, premium
or interest on the securities purchasable upon the exercise.
Other
Warrants
We will describe in the applicable prospectus supplement the
terms of the preferred stock warrants and common stock warrants
being offered, including the following:
|
|
|
|
|
the title of the warrants;
|
|
|
|
the securities for which the warrants are exercisable;
|
|
|
|
the price or prices at which the warrants will be issued;
|
18
|
|
|
|
|
the number of the warrants issued with each share of preferred
stock or common stock;
|
|
|
|
any provisions for adjustment of the number or amount of shares
of preferred stock or common stock receivable upon exercise of
the warrants or the exercise price of the warrants;
|
|
|
|
if applicable, the date on and after which the warrants and the
related preferred stock or common stock shares will be
separately transferrable;
|
|
|
|
if applicable, a discussion of the material U.S. federal
income tax considerations applicable to the exercise of the
warrants;
|
|
|
|
any other terms of the warrants, including terms, procedures and
limitations relating to the exchange and exercise of the
warrants;
|
|
|
|
the date on which the right to exercise the warrants will
commence, and the date on which the right will expire; and
|
|
|
|
the maximum or minimum number of the warrants which may be
exercised at any time.
|
Exercise of
Warrants
Each warrant will entitle the holder of the warrant to purchase
for cash at the exercise price set forth in the applicable
prospectus supplement the principal amount of debt securities or
shares of preferred stock or common stock being offered. Holders
may exercise warrants at any time up to the close of business on
the expiration date set forth in the applicable prospectus
supplement. After the close of business on the expiration date,
unexercised warrants are void.
Holders may exercise warrants as set forth in the prospectus
supplement relating to the warrants being offered. Upon receipt
of payment and the warrant certificate properly completed and
duly executed at the corporate trust office of the warrant agent
or any other office indicated in the prospectus supplement, we
will, as soon as practicable, forward the debt securities,
shares of preferred stock or common stock purchaseable upon the
exercise. If less than all of the warrants represented by the
warrant certificate are exercised, we will issue a new warrant
certificate for the remaining warrants.
DESCRIPTION OF
UNITS
We may issue securities in units, each consisting of two or more
types of securities. For example, we might issue units
consisting of a combination of preferred stock and warrants to
purchase common stock. If we issue units, the prospectus
supplement relating to the units will contain the information
described above with regard to each of the securities that is a
component of the units. In addition, each prospectus supplement
relating to units will:
|
|
|
|
|
state how long, if at all, the securities that are components of
the units must be traded in units, and when they can be traded
separately;
|
|
|
|
state whether we will apply to have the units traded on a
securities exchange or securities quotation system; and
|
|
|
|
describe how, for U.S. federal income tax purposes, the
purchase price paid for the units is to be allocated among the
component securities.
|
19
PLAN OF
DISTRIBUTION
We may sell the securities described in this prospectus from
time to time in one or more transactions:
|
|
|
|
|
to purchasers directly;
|
|
|
|
to underwriters for public offering and sale by them;
|
|
|
|
through agents;
|
|
|
|
through dealers; or
|
|
|
|
through a combination of any of the foregoing methods of sale.
|
We may distribute the securities from time to time in one or
more transactions at
|
|
|
|
|
a fixed price or prices, which may be changed;
|
|
|
|
market prices prevailing at the time of sale;
|
|
|
|
prices related to such prevailing market prices; or
|
|
|
|
negotiated prices.
|
Direct
Sales
We may sell the securities directly to institutional investors
or others who may be deemed to be underwriters within the
meaning of the Securities Act, with respect to any resale of the
securities. A prospectus supplement will describe the terms of
any sale of securities we are offering hereunder.
To
Underwriters
The applicable prospectus supplement will name any underwriter
involved in a sale of securities. Underwriters may offer and
sell securities at a fixed price or prices, which may be
changed, or from time to time at market prices or at negotiated
prices. Underwriters may be deemed to have received compensation
from us from sales of securities in the form of underwriting
discounts or commissions and may also receive commissions from
purchasers of securities for whom they may act as agent.
Underwriters may be involved in any of the market offering of
equity securities by or on our behalf.
Underwriters may sell securities to or through dealers, and such
dealers may receive compensation in the form of discounts,
concessions or commissions from the underwriters
and/or
commissions (which may be changed from time to time) from the
purchasers for whom they may act as agent.
Unless otherwise provided in a prospectus supplement, the
obligations of any underwriters to purchase securities will be
subject to certain conditions precedent, and the underwriters
will be obligated to purchase all the securities if any are
purchased.
Through Agents
and Dealers
We will name any agent involved in a sale of securities, as well
as any commissions payable by us to such agent, in a prospectus
supplement. Unless we indicate differently in the prospectus
supplement, any such agent will be acting on a reasonable
efforts basis for the period of its apportionment.
If we utilize a dealer in the sale of the securities being
offered pursuant to this prospectus, we will sell the securities
to the dealer, as principal. The dealer may then resell the
securities to the public at varying prices to be determined by
the dealer at the time of resale.
20
Delayed Delivery
Contracts
If we so specify in the applicable prospectus supplement, we
will authorize underwriters, dealers and agents to solicit
offers by certain institutions to purchase the securities
pursuant to contracts providing for payment and delivery on
future dates. Such contracts will be subject to only those
conditions set forth in the applicable prospectus supplement.
The underwriters, dealers and agents will not be responsible for
the validity or performance of the contracts. We will set forth
in the prospectus supplement relating to the contracts the price
to be paid for the securities, the commissions payable for
solicitation of the contracts and the date in the future for
delivery of the securities.
General
Information
Underwriters, dealers and agents participating in a sale of the
securities may be deemed to be underwriters as defined in the
Securities Act, and any discounts and commissions received by
them, and any profit realized by them on resale of the
securities, may be deemed to be underwriting discounts and
commissions under the Securities Act. We may have agreements
with underwriters, dealers and agents to indemnify them against
certain civil liabilities, including liabilities under the
Securities Act, and to reimburse them for certain expenses.
Shares of our common stock are quoted on the Nasdaq Global
Select Market. Unless otherwise specified in the related
prospectus supplement, all securities we offer, other than
common stock, will be new issues of securities with no
established trading market. Any underwriter may make a market in
these securities, but will not be obligated to do so and may
discontinue any market making at any time without notice. We may
apply to list any series of debt securities, preferred stock or
warrants on an exchange, but we are not obligated to do so.
Therefore, there may not be liquidity or a trading market for
any series of securities.
Underwriters, dealers or agents who may become involved in the
sale of our securities may be customers of, engage in
transactions with and perform other services for us in the
ordinary course of their business for which they receive
compensation.
LEGAL
MATTERS
Certain legal matters in connection with the securities will be
passed upon for us by OMelveny & Myers LLP.
EXPERTS
The consolidated financial statements, and the related financial
statement schedule, incorporated in this prospectus by reference
from the Companys Annual Report on
Form 10-K
for the year ended October 2, 2009, and the effectiveness
of Conexant Systems, Inc.s internal control over financial
reporting have been audited by Deloitte & Touche LLP,
an independent registered public accounting firm, as stated in
their reports, which are incorporated herein by reference. Such
consolidated financial statements and financial statement
schedule have been so incorporated in reliance upon the reports
of such firm given upon their authority as experts in accounting
and auditing.
21
14,000,000 Shares
Conexant Systems,
Inc.
Common Stock
PROSPECTUS
SUPPLEMENT
Goldman, Sachs &
Co.
Oppenheimer &
Co.